<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical manifestations of Sjögren’s disease: Extraglandular disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical manifestations of Sjögren’s disease: Extraglandular disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical manifestations of Sjögren’s disease: Extraglandular disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan N Baer, MD, MACR
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert I Fox, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Philip Seo, MD, MHS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 22, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sjögren’s disease (SjD) is a chronic systemic autoimmune disorder characterized by autoimmune-induced inflammation of exocrine glands, particularly the lacrimal and salivary glands, with resultant dry eyes and dry mouth. However, the clinical manifestations of SjD include both exocrine gland involvement and extraglandular disease features [
         <a href="#rid1">
          1
         </a>
         ]. SjD occurs in a primary form not associated with other diseases and a secondary form that complicates or overlaps other rheumatic conditions, most commonly rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).
        </p>
        <p>
         In both primary and secondary SjD, decreased exocrine gland function leads to a combination of dry eye (keratoconjunctivitis sicca) and dry mouth (xerostomia) symptoms [
         <a href="#rid2">
          2,3
         </a>
         ]. In addition, a variety of other disease manifestations can occur that may affect a range of tissues involving most organ systems.
        </p>
        <p>
         The extraglandular disease manifestations of SjD will be reviewed here. The exocrine manifestations, diagnosis, treatment, and prognosis of both sicca and extraglandular manifestations are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5607.html" rel="external">
          "Clinical manifestations of Sjögren's disease: Exocrine gland disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">
          "Diagnosis and classification of Sjögren’s disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14922.html" rel="external">
          "Treatment of dry eye in Sjögren’s disease: General principles and initial therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14923.html" rel="external">
          "Treatment of dry mouth and other non-ocular sicca symptoms in Sjögren’s disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14921.html" rel="external">
          "Overview of the management and prognosis of Sjögren's disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H53038006">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The extraglandular manifestations of Sjögren’s disease (SjD) arise from diverse pathogenetic mechanisms [
         <a href="#rid4">
          4
         </a>
         ]. Some represent autoimmune-induced inflammation centered on ductal epithelial structures in various organs, such as the liver (eg, primary biliary cholangitis [PBC; previously referred to as primary biliary cirrhosis]) and kidney (eg, interstitial nephritis). These are akin to the inflammation occurring in the salivary and lacrimal glands (termed "autoimmune epithelitis" by some authors) and tend to be relatively stable and chronic.
        </p>
        <p>
         Other extraglandular manifestations, such as glomerulonephritis and vasculitis, arise from immune-complex deposition. These develop most often in the context of cryoglobulinemia and may have a higher degree of morbidity and mortality compared with the immune response in ductal epithelial structures. Additionally, some manifestations relate to lymphoproliferation, such as lymphocytic interstitial pneumonitis (LIP) and lymphoma. The pathogenesis of other extraglandular manifestations is not well-understood; a prime example is the fatigue that occurs in many patients. The pathogenesis of SjD is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5620.html" rel="external">
          "Pathogenesis of Sjögren’s disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EXTRAGLANDULAR ORGAN INVOLVEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H53039305">
         <span class="h2">
          Disease spectrum
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many organs other than the exocrine glands may be affected in patients with Sjögren’s disease (SjD); these include the skin and joints; the lungs, heart, and gastrointestinal tract, including the pancreas and liver; the kidneys, bladder, and gynecologic system; and both the peripheral nervous system (PNS) and central nervous system (CNS) [
         <a href="#rid1">
          1
         </a>
         ]. Additionally, hematologic abnormalities are often present and there is an increased risk of lymphoproliferative disorders. Vascular disease, including cutaneous vasculitis and Raynaud phenomenon, may occur. Some extraglandular manifestations result from SjD itself, while others result from comorbid rheumatic or other autoimmune disease. Examples of the latter include autoimmune thyroid disorders, neuromyelitis optica, and celiac disease. The presence of SjD in a pregnant woman also has potential implications for the fetus and newborn during gestation and after delivery. (See
         <a class="local">
          'Pregnancy'
         </a>
         below.)
        </p>
        <p>
         The relatively common overlap of SjD with other autoimmune diseases may confound the interpretation of its extraglandular manifestations, since some organ involvement may not be unique to SjD but instead reflects overlap with another autoimmune disorder that may be fully or only partially expressed [
         <a href="#rid5">
          5
         </a>
         ]. In addition, the presence of an associated rheumatic disease may increase the risk of lymphoma development in SjD [
         <a href="#rid6">
          6
         </a>
         ]. In some cases (eg, interstitial cystitis, psychiatric symptoms), it is unclear whether abnormalities are related to the SjD itself or an associated but separate condition. However, the presence of relatively disease-specific autoantibodies in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), myositis, and systemic sclerosis (SSc, scleroderma) may help in making these distinctions, particularly when these antibodies are found in SjD patients with overlap features of another systemic rheumatic disease.
        </p>
        <p>
         A series of different classification criteria has been used to define and characterize SjD; thus, different classification criteria have been used in the various studies that describe the frequency with which an area or organ may be affected in SjD patients. This has resulted in varying estimates of the frequency and severity of particular clinical manifestations [
         <a href="#rid7">
          7,8
         </a>
         ]. Most information cited in this topic review relied upon the 2002 American European Consensus Group (AECG) classification criteria [
         <a href="#rid9">
          9,10
         </a>
         ]. These differed from earlier criteria for SjD in their requirement for either anti-SSA and/or anti-SSB antibodies or the finding of focal lymphocytic sialadenitis with a focus score of 1 or higher on a minor salivary gland biopsy (ie, a positive lip biopsy). Thus, publications using the AECG criteria excluded patients who might have dry eyes and dry mouth but lacked both of these other features (serology and histopathology).
        </p>
        <p>
         In 2016, a different set of criteria was jointly approved by the American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR; formerly known as European League Against Rheumatism) that differed from the AECG criteria in several respects, including the exclusion of subjective ocular or oral dryness, anti-La/SSB antibodies (when present without anti-Ro/SSA antibodies), parotid scintigraphy, and sialography as criteria. The criteria are only applicable to any patient with at least one symptom of ocular or oral dryness, salivary glandular enlargement, or a systemic manifestation typical of SjD. The criteria were specifically validated for primary SjD but can be applied to SjD in association with other autoimmune diseases pending additional study. The ACR/EULAR criteria mirror the earlier 2002 criteria with their requirement for either positive anti-Ro/SSA serology or a positive lip biopsy [
         <a href="#rid11">
          11,12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">
          "Diagnosis and classification of Sjögren’s disease", section on 'Classification criteria'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Skin
         </span>
         <span class="headingEndMark">
          —
         </span>
         The major skin findings in SjD include [
         <a href="#rid13">
          13
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Xerosis (ie, abnormal dryness) (see
         <a class="local">
          'Xerosis'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Purpura, associated with vascular or hematologic abnormalities (see
         <a class="local">
          'Cutaneous vasculitis'
         </a>
         below and
         <a class="local">
          'Hypergammaglobulinemia and hypogammaglobulinemia'
         </a>
         below and
         <a class="local">
          'Cryoglobulins'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Raynaud phenomenon (see
         <a class="local">
          'Raynaud phenomenon'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cutaneous vasculitis (see
         <a class="local">
          'Cutaneous vasculitis'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Annular erythema (see
         <a class="local">
          'Annular erythema'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other manifestations, including eyelid dermatitis and angular cheilitis (see
         <a class="local">
          'Other skin lesions'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Xerosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common cutaneous features of SjD are dryness and its sequela, pruritus [
         <a href="#rid14">
          14-19
         </a>
         ]. Xerosis is estimated to occur in 31 to 72 percent of patients with SjD and is characterized by dry, scaly skin, most often affecting the lower extremities and axillary creases [
         <a href="#rid14">
          14,19
         </a>
         ]. In a clinical trial of 120 patients with primary SjD with recent-onset or systemic disease, 48 percent rated their cutaneous dryness as 50 mm or more on a 100 mm visual analog scale of severity at baseline [
         <a href="#rid20">
          20
         </a>
         ]. The xerosis has been variably attributed to a specific alteration in the protective function of the skin's outer layer, the stratum corneum, and to decreased sebaceous or sweat gland secretion [
         <a href="#rid16">
          16,17,21
         </a>
         ]. Quantitative analyses of sweating and skin barrier function in patients with SjD compared with controls have yielded inconsistent results [
         <a href="#rid17">
          17,21-23
         </a>
         ]. In addition, inflammation of the eccrine glands has not been a consistent finding [
         <a href="#rid24">
          24
         </a>
         ]. Factors associated with xerosis include older age, frequent bathing, and low humidity. Symptoms tend to be worse in the winter in cold climates.
        </p>
        <p class="headingAnchor" id="H6598209">
         <span class="h3">
          Raynaud phenomenon
         </span>
         <span class="headingEndMark">
          —
         </span>
         Raynaud phenomenon has been reported in 13 to 30 percent of patients with SjD [
         <a href="#rid25">
          25,26
         </a>
         ]. It is more prevalent and severe in those patients with anticentromere antibodies [
         <a href="#rid27">
          27
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7543.html" rel="external">
          "Clinical manifestations and diagnosis of Raynaud phenomenon"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Cutaneous vasculitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cutaneous vasculitis occurs in approximately 4 to 10 percent of patients with primary SjD [
         <a href="#rid20">
          20,28-30
         </a>
         ]. It typically involves capillaries, arterioles, and venules, which leads to clinical manifestations typical of small-vessel vasculitis. Palpable purpura is the most common sign, but urticarial lesions, macules, papules, and small ulcerated areas may also occur. The lesions are commonly distributed over the lower extremities, but urticarial lesions are occasionally seen over the arms, the trunk, or even the face [
         <a href="#rid31">
          31,32
         </a>
         ]. Two forms of histopathology have been described [
         <a href="#rid33">
          33
         </a>
         ]. One form is typical of leukocytoclastic vasculitis; there is infiltration of the vessel walls by neutrophils with fibrinoid necrosis, lumen occlusion, leukocytoclasis, or erythrocyte extravasation. The second is characterized by invasion and disruption of the vessel wall by mononuclear cells. (See
         <a class="medical medical_review" href="/z/d/html/8241.html" rel="external">
          "Overview of cutaneous small vessel vasculitis", section on 'Clinical presentation'
         </a>
         .)
        </p>
        <p>
         The minority of patients who have medium-sized vessel disease can develop large cutaneous ulcers and internal organ involvement that mimics polyarteritis nodosa or rheumatoid vasculitis. SjD patients with this type of vasculitis usually have cryoglobulins [
         <a href="#rid34">
          34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8245.html" rel="external">
          "Clinical manifestations and diagnosis of polyarteritis nodosa in adults", section on 'Skin disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8237.html" rel="external">
          "Clinical manifestations and diagnosis of rheumatoid vasculitis", section on 'Cutaneous vasculitis'
         </a>
         .)
        </p>
        <p>
         Because of the frequency with which cutaneous vasculitis in SjD is associated with antibodies to the Ro/SSA antigen [
         <a href="#rid35">
          35
         </a>
         ], this complication of SjD may be difficult to distinguish from the benign hyperglobulinemic purpura of Waldenström [
         <a href="#rid31">
          31,36,37
         </a>
         ]. This latter entity is characterized by recurrent purpuric lesions (usually on the lower extremities), an elevated erythrocyte sedimentation rate (ESR), anemia, leukopenia, normal platelet counts, polyclonal hypergammaglobulinemia, and antibodies to the Ro/SSA antigen (see
         <a class="medical medical_review" href="/z/d/html/1818.html" rel="external">
          "The anti-Ro/SSA and anti-La/SSB antigen-antibody systems"
         </a>
         ). It can be primary, especially in young women, and secondary, most frequently in SjD, RA, and SLE, and rarely in patients with lymphoma and multiple myeloma. In a study of a large Italian multicenter cohort, stratification of SjD patients with hypergammaglobulinemic purpura by the presence or absence of cryoglobulins revealed important clinical and biologic differences; those with cryoglobulins were at increased risk of lymphoma and peripheral nerve and renal involvement [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         The development of cutaneous vasculitis may have important prognostic implications, as such patients are more likely than those lacking vasculitis to develop other extraglandular manifestations, including lymphoma, and to die of disease-related complications [
         <a href="#rid32">
          32,39,40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Annular erythema
         </span>
         <span class="headingEndMark">
          —
         </span>
         A cutaneous eruption characterized as annular erythema, has been described in a minority of patients with SjD [
         <a href="#rid41">
          41,42
         </a>
         ]. It was described as a manifestation of primary SjD in Japanese patients in a number of case reports in the 1980s and 1990s. Reports of this skin lesion in SjD were initially rare in Western populations. However, in a 2014 analysis of a Spanish cohort of primary SjD, the prevalence of annular erythema was 9 percent [
         <a href="#rid41">
          41
         </a>
         ]. The annular erythema resembles but may be distinct from subacute cutaneous lupus (SCLE), which may also develop in patients with SjD. Annular erythema occurs more commonly in women and in patients with antibodies to Ro/SSA and/or La/SSB antigens [
         <a href="#rid41">
          41,42
         </a>
         ]. Infrequently, other immunological markers are present.
        </p>
        <p>
         Annular erythema has three clinical patterns: an erythematous elevated indurated ring-like lesion resembling Sweet disease, a marginally scaling polycyclic erythema clinically very similar to SCLE, and an erythematous papular eruption resembling an insect bite reaction. None of these lesions result in scarring or atrophy. The eruption favors the face and neck but can involve the extremities and trunk. Photosensitivity is seen more frequently in White and Black than in Asian individuals. Histopathologic findings of annular erythema in SjD include a deep perivascular and or periappendageal lymphocytic infiltrate; the patients lack the specific epidermal changes of SCLE [
         <a href="#rid42">
          42
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1818.html" rel="external">
          "The anti-Ro/SSA and anti-La/SSB antigen-antibody systems"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4666.html" rel="external">
          "Overview of cutaneous lupus erythematosus", section on 'Subacute cutaneous lupus erythematosus'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Other skin lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other cutaneous manifestations associated with SjD include [
         <a href="#rid1">
          1,19
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Erythema multiforme-like lesions. Such lesions can occur in association with anti-SSA/Ro and/or anti-SSB/La antibodies and rheumatoid factor (RF), usually in patients with SLE or SLE/SS overlap [
         <a href="#rid43">
          43
         </a>
         ]. This is known as Rowell syndrome and may be associated with chilblains or pernio.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Erythema nodosum. (See
         <a class="medical medical_review" href="/z/d/html/5612.html" rel="external">
          "Erythema nodosum"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Livedo reticularis. (See
         <a class="medical medical_review" href="/z/d/html/13769.html" rel="external">
          "Evaluation of adults with cutaneous lesions of vasculitis", section on 'When to suspect cutaneous vasculitis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lichen planus. (See
         <a class="medical medical_review" href="/z/d/html/5662.html" rel="external">
          "Lichen planus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vitiligo. (See
         <a class="medical medical_review" href="/z/d/html/105109.html" rel="external">
          "Vitiligo: Pathogenesis, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Frontal fibrosing alopecia [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cutaneous amyloidosis [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Granuloma annulare. (See
         <a class="medical medical_review" href="/z/d/html/13705.html" rel="external">
          "Granuloma annulare: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Angular cheilitis. (See
         <a class="medical medical_review" href="/z/d/html/13654.html" rel="external">
          "Cheilitis", section on 'Angular cheilitis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Eyelid dermatitis. (See
         <a class="medical medical_review" href="/z/d/html/5607.html" rel="external">
          "Clinical manifestations of Sjögren's disease: Exocrine gland disease", section on 'Dry eye'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Musculoskeletal
         </span>
         <span class="headingEndMark">
          —
         </span>
         SjD may be associated with both joint and muscle manifestations, including arthralgia and (less often) arthritis, as well as myopathy, which is often asymptomatic. (See
         <a class="local">
          'Joints'
         </a>
         below and
         <a class="local">
          'Muscles'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          Joints
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 50 percent of patients with primary SjD report arthralgia, with or without evidence of arthritis [
         <a href="#rid46">
          46
         </a>
         ]. The arthropathy is usually symmetric, intermittent, nonerosive on plain radiographs, and nondeforming. The hands, wrists, and knees are preferentially affected [
         <a href="#rid47">
          47
         </a>
         ]. Ultrasonography of the hand and wrist joints may detect subclinical synovitis and erosions in patients with hand pain but equivocal clinical joint examinations [
         <a href="#rid48">
          48,49
         </a>
         ]. In one study, the prevalence of synovitis was 21.7 percent and that of erosions was 34.8 percent, when assessed with ultrasonography. The erosions were predominantly in the wrist joints [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
         RF was found in approximately 40 percent of patients with SjD in one large series, and was more common in patients with than without articular symptoms (45 versus 33 percent) [
         <a href="#rid35">
          35
         </a>
         ]. Anti-citrullinated peptide antibodies (ACPA) are detected in 5 to 10 percent of patients with primary SjD [
         <a href="#rid50">
          50
         </a>
         ]. Patients with RF or ACPA defined a subset of SjD patients with more severe inflammatory arthritis, which was often erosive, and with a higher risk of progression to RA [
         <a href="#rid50">
          50-54
         </a>
         ]. (See
         <a class="local">
          'Autoantibodies'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h3">
          Muscles
         </span>
         <span class="headingEndMark">
          —
         </span>
         A mild inflammatory myopathy that is either subclinical or characterized by the insidious onset of proximal muscle weakness may occur in SjD. The frequency with which myopathy is found depends upon the extent to which it is sought; the reported incidence ranges from 1 to 14 percent [
         <a href="#rid55">
          55
         </a>
         ]. In the French Assessment of Systemic Signs and Evolution in Sjögren's Syndrome (ASSESS) cohort of 395 primary SjD patients with 5 or more years of follow-up, myositis was suspected in 38 patients but confirmed in only 4 patients (1 percent) after careful evaluation [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
         Inclusion body myositis has also been linked to SjD and should be sought in patients with more insidious onset of weakness with relatively low muscle enzyme elevations [
         <a href="#rid56">
          56,57
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/5163.html" rel="external">
          "Clinical manifestations and diagnosis of inclusion body myositis"
         </a>
         ). It had a prevalence of 0.5 percent in the French ASSESS cohort of primary SjD patients, much higher than in the general population [
         <a href="#rid55">
          55
         </a>
         ]. Antibodies to cytosolic 5'-nucleotidase 1A are a marker of inclusion body myositis but can be detected in up to 36 percent of SjD patients without overt muscle disease [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
         The presence of significant muscle weakness and marked muscle enzyme elevations together with sicca symptoms may suggest SjD overlapping with another systemic rheumatic disease, such as antisynthetase syndrome. (See
         <a class="medical medical_review" href="/z/d/html/1831.html" rel="external">
          "Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7546.html" rel="external">
          "Mixed connective tissue disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H52196032">
         <span class="h2">
          Fatigue and fibromyalgia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fatigue is one of the most common symptoms in SjD, but its pathogenesis remains incompletely understood [
         <a href="#rid59">
          59
         </a>
         ]. Despite the association of fatigue with systemic disease activity, the levels of proinflammatory cytokines were inversely related to patient-reported levels of fatigue in a study of 159 participants of the United Kingdom Primary Sjögren's Syndrome Registry, arguing against a role for these cytokines in the genesis of fatigue in many SjD patients [
         <a href="#rid60">
          60
         </a>
         ]. By contrast, four independent patient-reported measures of fatigue improved in SjD patients treated with an RNase Fc fusion protein in a phase II randomized placebo-controlled clinical trial [
         <a href="#rid61">
          61
         </a>
         ]. Reduction of fatigue was the primary outcome measure in a randomized trial of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         in 17 patients with primary SjD [
         <a href="#rid62">
          62
         </a>
         ]; significant improvement from baseline in patient-reported fatigue was observed in the rituximab group compared with the placebo group. However, this finding was not confirmed in a subsequent randomized trial of rituximab involving 133 subjects [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
         Patients with SjD suffer from sleep disorders, usually due to disruption of sleep patterns by a cycle of xerostomia-stimulating polydipsia with resultant polyuria [
         <a href="#rid64">
          64
         </a>
         ]. Other causes of fatigue affecting some patients with SjD is hypothyroidism (see
         <a class="local">
          'Thyroid disease'
         </a>
         below) and depression [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
         Fibromyalgia may also engender fatigue in SjD; it had a prevalence of 15 to 31 percent in two large SjD cohorts [
         <a href="#rid65">
          65,66
         </a>
         ]. The high prevalence of fibromyalgia in SjD and other autoimmune rheumatic diseases has prompted a search for an autoimmune pathogenesis of fibromyalgia. Support for this has come from the demonstration that fibromyalgia symptoms can be induced in mice after the passive transfer of purified serum immunoglobulin (Ig) G from fibromyalgia patients [
         <a href="#rid67">
          67
         </a>
         ]. Binding of the transferred IgG to satellite glial cells and neurons in the murine dorsal root ganglia was demonstrated and postulated to explain an observed decrease in epidermal nerve fiber density in the mouse paw and increased sensitivity of their peripheral nociceptors. Dorsal root ganglionitis underlies some forms of peripheral nerve involvement in SjD (see
         <a class="medical medical_review" href="/z/d/html/120953.html" rel="external">
          "Neurologic manifestations of Sjögren's disease"
         </a>
         ) and might constitute a pathogenetic link with fibromyalgia.
        </p>
        <p>
         In some SjD patients, fatigue undoubtedly relates to disease activity, such as inflammatory arthritis, ocular pain and visual impairment, and more serious internal organ involvement (eg, interstitial pneumonitis). (See
         <a class="medical medical_review" href="/z/d/html/113735.html" rel="external">
          "Treatment of Sjögren's disease: Constitutional and non-sicca organ-based manifestations", section on 'Rituximab'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Thyroid disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evidence of thyroid disease, including some form of structural, hormonal, or thyroid autoantibody abnormalities, has been found in 10 to 70 percent of patients with primary SjD in a number of geographically diverse studies, with autoimmune thyroiditis being most common [
         <a href="#rid68">
          68-73
         </a>
         ]. Polyautoimmunity denotes the clustering of different autoimmune diseases in the same individual and may underlie this association [
         <a href="#rid74">
          74
         </a>
         ]. However, whether thyroid disease has a specific association with SjD remains uncertain, with some data suggesting there is no significant association.
        </p>
        <p>
         Support for a relationship comes from reports that the risk of developing SjD was significantly increased in women with thyroid disorders in a longitudinal population-based study in Taiwan [
         <a href="#rid75">
          75
         </a>
         ]. Moreover, autoimmune diseases, particularly autoimmune thyroid disease, tend to aggregate in the first-degree relatives of patients with primary SjD [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
         Other observations do not support a link between SjD and thyroid disease. As an example, patients with SjD, being older and predominantly female, would be expected to have a higher incidence of thyroid disease than the general population. Consistent with this, in a well-designed study that compared 160 patients with primary SjD with 75 age- and sex-matched controls from a primary care center, there was no statistically significant difference between the groups in the overall prevalence of thyroid disease or any particular type of thyroid disease [
         <a href="#rid77">
          77
         </a>
         ]. Similarly, in a case-control study from Turkey, the frequency of thyroid antibodies was not increased in patients with primary SjD compared with those with either RA, secondary SjD, or healthy controls [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Lungs
         </span>
         <span class="headingEndMark">
          —
         </span>
         The airways and interstitium are the primary targets of lung disease in SjD [
         <a href="#rid79">
          79-81
         </a>
         ]. Approximately 10 to 20 percent of SjD patients have clinically significant lung disease defined classically by symptoms and an abnormal pulmonary function test or chest radiograph [
         <a href="#rid82">
          82
         </a>
         ]. However, a far greater number of patients have lung abnormalities detectable with pulmonary function tests, bronchoalveolar lavage, and computed tomography (CT), and some may report cough or dyspnea [
         <a href="#rid81">
          81,82
         </a>
         ]. Consensus guidelines for the evaluation and management of pulmonary disease in SjD, developed by the Sjögren's Foundation, were published in 2020 [
         <a href="#rid83">
          83
         </a>
         ]. Interstitial lung disease will be reviewed very briefly here and is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4301.html" rel="external">
          "Interstitial lung disease associated with Sjögren's disease: Clinical manifestations, evaluation, and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Upper respiratory tract and airways
         </strong>
         – SjD may affect the upper respiratory tract as well as large and small airways. Involvement of exocrine glands in the upper airways leads to symptoms related to the nose, sinuses, and posterior pharynx in 50 to 70 percent of patients with SjD [
         <a href="#rid84">
          84
         </a>
         ]. Such patients can have recurrent nonallergic rhinitis and sinusitis. The most common symptom of laryngeal, tracheal, and bronchial involvement is a dry cough, which may be persistent and irritating. If the patient does not have other features of SjD, the diagnosis may be missed, and the patient may be treated incorrectly for asthma or bronchitis. Only 20 percent of affected patients have abnormalities that can be identified by rhinoscopy or indirect laryngoscopy [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Bronchial dryness becomes especially important in two situations. First, in the presence of upper airway infections, there is a tendency to develop mucus plug inspissation. This may be exacerbated by over-the-counter cold preparations that contain anticholinergic drugs. Second, mucus plugs can occur postoperatively, as a result of anticholinergic drugs given by the anesthetist and of the dehydrating effects of the operating room.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Saliva acts as a buffer for refluxed gastric acid and its deficiency can thus lead to laryngeal damage and symptoms of globus, excessive throat clearing, cough, and hoarseness. Lymphocytic infiltration of the submucosal glands in the nasopharynx, larynx, trachea, and bronchi leads to desiccation of the mucosa of the respiratory tree, alteration in the viscosity of the mucus, and impaired mucociliary clearance, resulting in a persistent dry cough, hoarseness, and nasal dryness and crusting [
         <a href="#rid85">
          85
         </a>
         ]. In cross-sectional studies of SjD patients, there is a high frequency of large airway disease, as evidenced by CT scanning and pulmonary function tests [
         <a href="#rid81">
          81
         </a>
         ]. Patients may report dry cough, recurrent bronchitis, and dyspnea. High-resolution CT imaging may show bronchial airway thickening, bronchiectasis, centrilobular nodules, reticular or reticulonodular infiltrates, and air trapping. Pulmonary function studies show varied and usually mild abnormalities, including reductions in maximal expiratory flows at 25 percent of vital capacity (MEF
         <sub>
          25
         </sub>
         ) and a reduced diffusing capacity for carbon monoxide [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The pathologic basis for airway disease in SjD has been largely deduced from analysis of lung biopsy material from patients with symptomatic interstitial lung disease. Bronchiolitis is the main airway lesion, including follicular, chronic, and obliterative forms [
         <a href="#rid86">
          86,87
         </a>
         ]. Follicular bronchiolitis has been specifically linked to connective tissue diseases, such as SjD and RA. It is characterized by the formation of hyperplastic lymphoid follicles in the bronchiolar walls leading to obstruction of the bronchiolar lumen [
         <a href="#rid88">
          88
         </a>
         ]. The ensuing submucosal and peribronchial fibrosis can also restrict the lumen. A valve phenomenon may ensue and result in lung cysts or bullae.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cystic lung disease
         </strong>
         – Thin-walled lung cysts are present in 12 to 46 percent of SjD patients [
         <a href="#rid89">
          89,90
         </a>
         ]. They are usually multiple, bilateral, located in the middle and lower lung zones, and associated with other pulmonary lesions, including pulmonary amyloidosis, lymphocytic interstitial pneumonitis, and lymphoma  (
         <a class="graphic graphic_diagnosticimage graphicRef126383" href="/z/d/graphic/126383.html" rel="external">
          image 1
         </a>
         ). The cysts often vary in size, may have internal septations, and are often found in conjunction with other radiographic abnormalities, including bronchiectasis, micronodules, ground-glass opacity, and/or air-trapping. They are an isolated radiologic lesion of the lung in a minority of patients. Most patients are asymptomatic. Affected patients tend to be older and have anti-Ro/SSA antibodies [
         <a href="#rid90">
          90
         </a>
         ]. In two prospective analyses, there was no change in the number or size of the cysts during median follow-up of four years [
         <a href="#rid89">
          89,90
         </a>
         ]. This form of cystic lung disease may be the presenting manifestation of SjD, and needs to be differentiated from lymphangioleiomyomatosis and pulmonary Langerhans cell histiocytosis [
         <a href="#rid91">
          91
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/107651.html" rel="external">
          "Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4334.html" rel="external">
          "Pulmonary Langerhans cell histiocytosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Interstitial lung disease
         </strong>
         – Interstitial lung disease in SjD has several forms, including non-specific interstitial pneumonitis (NSIP), usual interstitial pneumonitis (UIP), lymphocytic interstitial pneumonitis (LIP), and cryptogenic organizing pneumonia (COP) [
         <a href="#rid92">
          92,93
         </a>
         ]. Dyspnea and cough are the usual presenting symptoms. NSIP is the most common histopathologic lesion but is a form of lung injury common to a variety of connective tissue diseases and hypersensitivity reactions. These patients should be evaluated for possible overlap with other rheumatic diseases, including testing for antisynthetase and scleroderma-associated antibodies. LIP has a strong association with primary SjD. It is characterized by a lymphoplasmacytic infiltrates within the interstitium, often forming nodular lymphoid aggregates with or without germinal centers, and lymphocytes within alveolar spaces [
         <a href="#rid94">
          94
         </a>
         ]. Follicular bronchiolitis often coexists. Affected patients usually have a polyclonal or monoclonal gammopathy. LIP can be a precursor to a bronchus-associated lymphoid tissue (BALT) lymphoma. These are discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4301.html" rel="external">
          "Interstitial lung disease associated with Sjögren's disease: Clinical manifestations, evaluation, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Heart and cardiovascular system
         </span>
         <span class="headingEndMark">
          —
         </span>
         SjD may be associated with increased risk for cardiovascular disease. Pericarditis and myocardial disease may occur, but are rarely evident clinically, and heart block is also rare but may occur in adults with SjD.
        </p>
        <p>
         In cohort studies, SjD was an independent risk factor for arterial wall thickening (a marker of subclinical atherosclerosis) [
         <a href="#rid95">
          95,96
         </a>
         ], cerebrovascular events and myocardial infarction [
         <a href="#rid97">
          97-99
         </a>
         ], venous thromboembolism [
         <a href="#rid98">
          98
         </a>
         ], hypertension, and hypertriglyceridemia [
         <a href="#rid100">
          100
         </a>
         ]. In one study, the increased risk of cardiovascular disease was highest among those patients with both anti-Ro/SSA and anti-La/SSB antibodies [
         <a href="#rid98">
          98
         </a>
         ]. By contrast, in a study of 312 patients with primary SjD, the frequency of cardiovascular disease in primary SjD patients was no different from matched controls without autoimmune disease [
         <a href="#rid101">
          101
         </a>
         ]. Similarly, the risk of ischemic heart disease was modestly decreased among SjD patients, compared with controls, in a cross-sectional study of a large administrative database of inpatient encounters at United States hospitals [
         <a href="#rid102">
          102
         </a>
         ].
        </p>
        <p>
         Acute pericarditis and myocarditis are rare complications of primary SjD [
         <a href="#rid103">
          103,104
         </a>
         ], but echocardiographic evidence of prior pericarditis or left ventricular diastolic dysfunction is more common [
         <a href="#rid103">
          103
         </a>
         ]. In an echocardiographic study of 107 consecutive primary SjD patients without clinically apparent heart disease and 112 age- and sex-matched healthy controls, valvular regurgitation, clinically silent pericardial effusion, pulmonary hypertension, and increased left ventricular mass index were significantly more prevalent in the SjD patients [
         <a href="#rid105">
          105
         </a>
         ]. Hypocomplementemia, age, and cryoglobulinemia were predictors of some of these findings.
        </p>
        <p>
         Heart block is rare in adult SjD patients and is not consistently associated with anti-SSA/Ro antibodies [
         <a href="#rid106">
          106
         </a>
         ]. Congenital heart block may develop in the fetus of a pregnant woman with SjD as a result of transplacental passage of anti-SSA/Ro antibodies. (See
         <a class="medical medical_review" href="/z/d/html/6402.html" rel="external">
          "Neonatal lupus: Epidemiology, pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Gastrointestinal tract
         </span>
         <span class="headingEndMark">
          —
         </span>
         Manifestations of SjD related to the entire gastrointestinal tract, as well as the liver and pancreas, have been described. Dysphagia, nausea, dyspepsia and gastritis, celiac disease, hepatic abnormalities, and (usually subclinical) pancreatic disease have been observed. The oral manifestations of SjD are described elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5607.html" rel="external">
          "Clinical manifestations of Sjögren's disease: Exocrine gland disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oropharynx, upper gastrointestinal tract, and stomach
         </strong>
         – Dysphagia is common in SjD, but its occurrence correlates poorly with salivary flow rates [
         <a href="#rid107">
          107
         </a>
         ], arguing for mechanisms apart from a lack of saliva. Orofacial and pharyngeal muscle dysfunction and esophageal dysmotility have also been reported [
         <a href="#rid108">
          108-111
         </a>
         ], and gastric emptying may be delayed as a result of autonomic dysfunction [
         <a href="#rid112">
          112
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Nausea, epigastric pain, and dyspepsia are other frequent symptoms [
         <a href="#rid113">
          113
         </a>
         ]. An atrophic chronic gastritis was evident in 5 percent of a Spanish multicenter SjD cohort of 437 patients [
         <a href="#rid114">
          114
         </a>
         ]. Gastric biopsies in one study of seven patients were characterized by mononuclear cell infiltrates within the lamina propria, composed mostly of CD4-positive T cells [
         <a href="#rid115">
          115
         </a>
         ]. Achlorhydria and hypopepsinogenemia can also occur. In a Spanish cohort of 335 patients with primary SjD, 27 percent had antiparietal cell antibodies, but only 2 percent with these antibodies had pernicious anemia and/or atrophic gastritis [
         <a href="#rid116">
          116
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients who have gastritis may be infected with
         <em>
          Helicobacter pylori
         </em>
         , an organism associated with mucosa-associated lymphoid tissue (MALT) lymphoma of the salivary glands in rare patients [
         <a href="#rid117">
          117,118
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/18.html" rel="external">
          "Indications and diagnostic tests for Helicobacter pylori infection in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Celiac disease
         </strong>
         – Celiac disease (gluten enteropathy) may be more prevalent in patients with SjD than in the general population. In an Italian study of 354 patients with SjD and 14.298 age- and sex-matched control subjects, the prevalence of histologically confirmed celiac disease was greater in the patients with SjD than in the controls (6.78 versus 0.64 percent) [
         <a href="#rid119">
          119
         </a>
         ]. Similar results were noted in a Hungarian study of 111 patients [
         <a href="#rid120">
          120
         </a>
         ]. The reported prevalence of celiac disease in SjD is similar to that of celiac disease in disorders such as type 1 diabetes and autoimmune thyroid disease. (See
         <a class="medical medical_review" href="/z/d/html/4771.html" rel="external">
          "Diagnosis of celiac disease in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Liver
         </strong>
         – SjD is associated with hepatic abnormalities, including (usually mildly) abnormal biochemical tests and histologic changes of primary biliary cholangitis (PBC; previously referred to as primary biliary cirrhosis) or autoimmune hepatitis. The hepatic function test abnormalities may be hepatocellular or predominantly cholestatic in pattern and are persistent in 5 to 26 percent of patients [
         <a href="#rid121">
          121,122
         </a>
         ]. Other causes of liver dysfunction in SjD include hepatitis C virus infection, nonalcoholic fatty liver disease, and drug toxicity [
         <a href="#rid123">
          123
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with PBC have an 18 to 38 percent prevalence of SjD [
         <a href="#rid124">
          124
         </a>
         ]. However, clinically overt PBC is found in less than 4 percent of SjD patients in large cohorts [
         <a href="#rid8">
          8,114,116,125
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/3621.html" rel="external">
          "Clinical manifestations, diagnosis, and prognosis of primary biliary cholangitis"
         </a>
         ). Similarly, autoimmune hepatitis is present in less than 2 percent of primary SjD patients [
         <a href="#rid114">
          114,123
         </a>
         ]. In a large SjD cohort, antimitochondrial and anti-smooth muscle antibodies were present, respectively, in 8 and 62 percent of patients, raising the possibility that subclinical autoimmune liver disease is more common in SjD [
         <a href="#rid116">
          116
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pancreas
         </strong>
         – Since SjD is a disease of exocrine glands, involvement of the pancreas would be expected, but is rarely evident clinically. However, subclinical involvement has been documented in several studies [
         <a href="#rid107">
          107
         </a>
         ]. Among 12 SjD patients without known pancreatic disease, six had abnormal pancreatic tests, including three with morphologic changes of the pancreatic ductal system evident by secretin-stimulated MRCP and four with slightly reduced pancreatic function as judged by the Lundh test [
         <a href="#rid126">
          126
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         SjD has been reported in association with autoimmune sclerosing pancreatitis, a disorder associated with diffuse or localized swelling of the pancreas and narrowing of the pancreatic duct [
         <a href="#rid127">
          127,128
         </a>
         ]. However, some patients thought to have SjD and autoimmune pancreatitis may instead have IgG4-related systemic disease. (See
         <a class="medical medical_review" href="/z/d/html/5657.html" rel="external">
          "Autoimmune pancreatitis: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">
          "Diagnosis and classification of Sjögren’s disease", section on 'Nomenclature'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121220.html" rel="external">
          "Clinical manifestations and diagnosis of IgG4-related disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Urogenital disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immune-mediated renal disease, including interstitial nephritis, can occur in patients with SjD; as may bladder dysfunction with symptoms of interstitial nephritis and gynecologic symptoms including vulvovaginal dryness, pruritus, and dyspareunia.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Kidneys
         </strong>
         – Interstitial nephritis, renal tubular dysfunction leading to renal tubular acidosis and/or to decreased concentrating ability, and glomerular disease can occur in SjD. Renal involvement is discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7187.html" rel="external">
          "Kidney disease in primary Sjögren's disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bladder
         </strong>
         – Women with SjD may develop dysuria, urinary frequency, nocturia, and urgency. In the absence of a urinary tract infection, these symptoms in a patient with SjD may be secondary to interstitial cystitis. The frequency of this symptom complex was evaluated in a study of 870 Finnish women with SjD and of 1304 population controls [
         <a href="#rid129">
          129
         </a>
         ]. The presence of such urinary symptoms was 20-fold higher in those with SjD (4 versus 0.2 percent in controls). In a 2015 literature review, only 13 SjD patients with biopsy-confirmed interstitial cystitis were identified, suggesting that the association of these two diseases is rare [
         <a href="#rid130">
          130
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8085.html" rel="external">
          "Interstitial cystitis/bladder pain syndrome: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gynecologic manifestations
         </strong>
         – Gynecologic symptoms, including vulvovaginal dryness, pruritus, and dyspareunia, are common in SjD and can be a significant source of morbidity [
         <a href="#rid131">
          131
         </a>
         ]. Urogenital involvement may also be complicated by bacterial and candidal infections.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Dryness, pruritus, and dyspareunia may relate in part to the predilection of SjD for postmenopausal women. In one study, dyspareunia was noted to affect 40 percent of premenopausal SjD patients versus 3 percent in the healthy control population; however, half of the patients had an obvious etiology for dyspareunia [
         <a href="#rid132">
          132
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The vaginal mucosa does not have secretory glands, and its basal humidification and lubrication during sexual arousal is thus dependent on fluid transudation across the vaginal epithelium. Substantial increases in T-lymphocytic infiltrates have been observed in vaginal biopsies from patients with SjD compared with healthy controls, primarily in the lamina propria just below the epithelium [
         <a href="#rid133">
          133
         </a>
         ]. An effect of these infiltrates on fluid transudation has been postulated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The Bartholin and Skene glands at the vaginal vestibule have a minor role in lubrication of the vulva; their involvement in SjD has long been cited but never proven [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1850773760">
         <span class="h2">
          Vasculitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cutaneous vasculitis occurs in a significant minority of patients, but systemic necrotizing vasculitis is rare. A rash is the most common manifestation of vasculitis in SjD patients (see
         <a class="local">
          'Cutaneous vasculitis'
         </a>
         above). Rarely, patients may develop a necrotizing vasculitis of medium-sized arteries resembling polyarteritis nodosa [
         <a href="#rid134">
          134
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/8245.html" rel="external">
          "Clinical manifestations and diagnosis of polyarteritis nodosa in adults"
         </a>
         ). Similarly, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis has been reported in several case series of patients with primary SjD [
         <a href="#rid135">
          135
         </a>
         ]. Manifestations of cryoglobulinemia may account for the development of membranoproliferative glomerulonephritis, sensorimotor polyneuropathies, and cutaneous vasculitis in some patients. (See
         <a class="medical medical_review" href="/z/d/html/3062.html" rel="external">
          "Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6599746">
         <span class="h2">
          Neurologic disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of neurologic manifestations may occur in SjD, including a complex array of peripheral and CNS abnormalities. Peripheral neuropathy affects approximately 10 percent of patients. Estimates of CNS involvement vary quite widely, and the nature and frequency of CNS manifestations remain controversial. Neuropathic symptoms frequently precede the diagnosis of SjD, although other symptoms of SjD may be present. The neurologic manifestations of SjD are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/120953.html" rel="external">
          "Neurologic manifestations of Sjögren's disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1827967260">
         <span class="h2">
          Psychiatric disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Affective disorders are the most common psychiatric disturbance in SjD patients [
         <a href="#rid136">
          136,137
         </a>
         ]. Depression had a prevalence of 33 to 49 percent in small cohorts of primary SjD patients [
         <a href="#rid137">
          137-139
         </a>
         ]. The pathophysiologic basis of depression in SjD is not known; a response to the stress of chronic illness and an effect of proinflammatory cytokines on neural pathways have each been postulated [
         <a href="#rid139">
          139
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h2">
          Hematologic manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The hematologic manifestations of SjD include cytopenias, especially mild anemia and leukopenia (see
         <a class="local">
          'Cytopenias'
         </a>
         below); hypergammaglobulinemia (see
         <a class="local">
          'Hypergammaglobulinemia and hypogammaglobulinemia'
         </a>
         below); and monoclonal gammopathies, cryoglobulinemia, and lymphoma, and are primarily seen in patients with autoantibodies (particularly anti-SSA or anti-SSB antibodies).
        </p>
        <p class="headingAnchor" id="H1827967355">
         <span class="h3">
          Cytopenias
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with SjD may exhibit abnormal counts in any cell line, and patients with cytopenia often have involvement of more than one cell line. However, anemia is usually mild when present, and differential white blood cell counts are most often normal, even though neutropenia, eosinophilia, lymphopenia, lymphocytosis, and monocytosis may all occur. The new development of a cytopenia in a patient with established SjD can be an early sign of underlying lymphoma. Findings include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anemia – A normochromic, normocytic anemia, which occurs in approximately 20 percent [
         <a href="#rid8">
          8,28,39
         </a>
         ]. It is usually mild and correlates with the presence of other forms of extraglandular disease, such as cutaneous vasculitis, renal involvement, peripheral neuropathy, and cryoglobulinemia [
         <a href="#rid39">
          39
         </a>
         ]. Autoimmune hemolytic anemia had a prevalence of 2.8 percent in a cohort of 565 SjD patients hospitalized in China [
         <a href="#rid140">
          140
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Leukopenia – Leukopenia, which has been reported in 12 to 22 percent of SjD cohorts [
         <a href="#rid8">
          8,39,141,142
         </a>
         ]. The differential blood counts are most often normal. The white blood count may fluctuate between normal and low values during the course of disease. In most patients, the leukopenia is mild and is not associated with an increased rate of infections. However, in one study neutropenia was identified in 33 percent of a cohort of SjD patients during longitudinal follow-up, and these patients had a higher incidence of hospital admission caused by infection [
         <a href="#rid142">
          142
         </a>
         ]. The rate of hospitalization was increased especially in patients with neutrophil counts of less than 1000 cells/microL.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mild thrombocytopenia (eg, &gt;50,000 and &lt;150,000 cells/microL) is present in 5 to 13 percent of patients [
         <a href="#rid8">
          8,39
         </a>
         ]; severe thrombocytopenia is rare, in contrast to SLE.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1827967401">
         <span class="h3">
          Hypergammaglobulinemia and hypogammaglobulinemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypergammaglobulinemia is common in patients with SjD, with a prevalence estimated at 36 to 62 percent [
         <a href="#rid39">
          39,68,143
         </a>
         ]. It may be either polyclonal or monoclonal (see
         <a class="local">
          'Monoclonal gammopathy'
         </a>
         below). Patients with polyclonal hypergammaglobulinemia have been reported with total globulin levels as high as 14 g/dL [
         <a href="#rid144">
          144
         </a>
         ].
        </p>
        <p>
         The presence of hypergammaglobulinemia is closely linked to that of anti-Ro/SSA and anti-La/SSB antibodies and RF [
         <a href="#rid39">
          39,145
         </a>
         ]. Elevated levels of IgG in SjD strongly predict the presence of abnormalities consistent with a positive minor salivary gland lip biopsy [
         <a href="#rid146">
          146
         </a>
         ]. Hypergammaglobulinemia may account for some cases of elevated ESR in SjD that occur in the absence of infection, systemic vasculitis, or other apparent causes such as benign hypergammaglobulinemia purpura of Waldenström.
        </p>
        <p>
         Hypogammaglobulinemia is less common than hypergammaglobulinemia and may reflect underlying common variable immunodeficiency [
         <a href="#rid39">
          39
         </a>
         ]; it may also develop in patients with established SjD as a sign of underlying lymphoma [
         <a href="#rid147">
          147
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1827967497">
         <span class="h3">
          Monoclonal gammopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Monoclonal gammopathies occur in patients with SjD, being detected in one study in approximately 20 percent of those patients in whom immunoelectrophoresis was performed [
         <a href="#rid39">
          39
         </a>
         ]. Monoclonal IgG proteins were the most common class detected, followed by IgM. The presence of a monoclonal gammopathy was usually associated with the presence of hypergammaglobulinemia, cryoglobulinemia, or hematologic neoplasia, especially lymphoma and myeloma [
         <a href="#rid148">
          148
         </a>
         ]. The incidence of lymphoma is increased among SjD patients with a monoclonal IgM-kappa protein and/or mixed monoclonal cryoglobulinemia [
         <a href="#rid149">
          149,150
         </a>
         ].
        </p>
        <p>
         The risk of multiple myeloma is increased in SjD patients relative to the general population. In a study utilizing a nationwide Taiwan health insurance database, the standardized incidence ratio (SIR) was 6.1 (95% CI 2.0-14.2) [
         <a href="#rid151">
          151
         </a>
         ]. An increased risk was also observed in three cohort studies, one from Sweden (hazard ratio [HR] 2.9; 95% CI 0.9-8.7), one from a single tertiary care center in China (SIR 37.9; 95% CI 4.6-136.7), and one from a Spanish registry of SjD patients (SIR 36.17; 95% CI 25.44-51.43) [
         <a href="#rid152">
          152-154
         </a>
         ]. Similarly, a personal history of SjD was increased among patients with Waldenström macroglobulinemia (odds ratio [OR] 12.1; 95% CI 3.3-45.0) in an analysis of Swedish population-based registries [
         <a href="#rid155">
          155
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1827967618">
         <span class="h3">
          Cryoglobulins
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cryoglobulins are present in 9 to 16 percent of patients with primary SjD [
         <a href="#rid156">
          156,157
         </a>
         ]; these patients usually had type II (monoclonal/polyclonal) mixed cryoglobulinemia [
         <a href="#rid156">
          156
         </a>
         ]. The monoclonal component is usually an IgM kappa with RF activity [
         <a href="#rid149">
          149,156
         </a>
         ]. Cryoglobulins in SjD are associated with the presence of cutaneous leukocytoclastic vasculitis, hypocomplementemia, and hepatitis C infection [
         <a href="#rid156">
          156
         </a>
         ]. The triad of cryoglobulinemia, hypocomplementemia, and purpura correlates strongly with severe disease complications and death [
         <a href="#rid35">
          35
         </a>
         ]. In one series, patients with type II mixed cryoglobulinemia exhibited an increased risk for the development of a B-cell lymphoma (6 of 18 patients) [
         <a href="#rid149">
          149
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1825.html" rel="external">
          "Overview of cryoglobulins and cryoglobulinemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1827967695">
         <span class="h3">
          Lymphoma
         </span>
        </p>
        <p class="headingAnchor" id="H52196773">
         <span class="h4">
          Prevalence and risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with SjD have an increased risk of non-Hodgkin lymphoma compared with the general population, a finding shared by diverse autoimmune disorders such as RA, SLE, and celiac disease, but which is highest for SjD [
         <a href="#rid6">
          6,158
         </a>
         ]. This increased risk is evident for both primary and secondary forms of SjD. In a pooled analysis of 29,423 participants in 12 case-control studies on risk factors, the relative risk of non-Hodgkin lymphoma was 4.8 for primary and 9.6 for secondary SjD (overall risk 6.6) [
         <a href="#rid6">
          6
         </a>
         ]. Estimates of the lifetime risk of non-Hodgkin lymphoma range from approximately 5 to 10 percent [
         <a href="#rid39">
          39,40,159-161
         </a>
         ], which is 5 to 44 times higher than that of the normal population [
         <a href="#rid29">
          29,162-164
         </a>
         ]. In a systematic review of 7 studies, the prevalence of lymphoma following diagnosis was 4 percent during the first 5 years, 10 percent at 15 years, and 18 percent at 20 years [
         <a href="#rid165">
          165
         </a>
         ].
        </p>
        <p>
         Clinical, histopathologic, and laboratory features identify patients with SjD who are at increased risk for developing lymphoma [
         <a href="#rid166">
          166
         </a>
         ]. Persistent salivary gland enlargement is the most important clinical risk factor [
         <a href="#rid167">
          167
         </a>
         ]. Others include cutaneous vasculitis, lymphadenopathy, splenomegaly, cryoglobulinemia, and the development of glomerulonephritis [
         <a href="#rid168">
          168
         </a>
         ]. The presence of a high focus score and possibly germinal center-like structures on labial salivary gland biopsies, performed at the time of initial patient evaluation, are both predictive of lymphoma [
         <a href="#rid169">
          169-171
         </a>
         ] and provide an additional rationale, other than diagnostic, for the labial gland biopsy [
         <a href="#rid172">
          172
         </a>
         ]. Laboratory markers include mixed monoclonal cryoglobulinemia, low serum complement C3 or C4, an IgM kappa monoclonal protein, and neutropenia.
        </p>
        <p>
         A multicenter case-control study involving 101 patients with primary SjD who developed lymphoma confirmed the association of salivary gland enlargement, low complement C4, cryoglobulinemia, and lymphopenia with lymphoma development in SjD, and also identified RF and disease activity as risk factors [
         <a href="#rid173">
          173
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H52196801">
         <span class="h4">
          Histopathology and transition to lymphoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         SjD is characterized by polyclonal B-cell activation and by chronic inflammation of the exocrine glands. In most patients, lymphoproliferation remains confined to the glandular tissue and does not undergo malignant transformation. The transition from SjD to lymphoma is a process that requires many years. In two series, the diagnosis of lymphoma occurred at a mean of 6.5 to 7.5 years after the diagnosis of SjD [
         <a href="#rid40">
          40,160
         </a>
         ].
        </p>
        <p>
         The mechanisms by which SjD predisposes some patients to develop lymphoma are matters of ongoing study [
         <a href="#rid164">
          164
         </a>
         ]. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (also called MALT lymphoma) can arise in the salivary glands from a reactive lymphoid infiltrate called lymphoepithelial sialadenitis or benign lymphoepithelial lesion [
         <a href="#rid174">
          174
         </a>
         ]. Clinically, patients with lymphoepithelial sialadenitis have persistent salivary gland enlargement. The distinction between this benign lymphoid proliferation and malignant MALT lymphoma can be difficult and requires integration of findings from histopathologic, immunohistochemical, and flow cytometric analyses of appropriate biopsy material [
         <a href="#rid175">
          175-177
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4733.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT)"
         </a>
         .)
        </p>
        <p>
         In the benign lesion, there is progressive polyclonal B- and T-cell lymphoid infiltration of the salivary gland parenchyma, leading to atrophy and destruction of acini. The lymphoid infiltrate is initially periductal but then extends peripherally and contains lymphoid follicles with germinal centers. Centrocyte-like B lymphocytes present in a zone beyond the mantle of these follicles focally invade the ductal epithelium. Lymphoepithelial lesions are a characteristic finding within the lymphoid infiltrate and likely represent a later stage of this process. They are comprised of "islands" of hyperplastic ductal epithelium, both invaded and surrounded by centrocyte-like B cells, the latter process leading to a perilesional halo.
        </p>
        <p>
         The progression of this pathologic lesion to MALT lymphoma is characterized by the expansion of the population of centrocyte-like B cells to form broad confluent zones around the lymphoepithelial lesions. In more advanced cases, the infiltrating centrocyte-like cells have a monotonous blast-like morphology [
         <a href="#rid178">
          178
         </a>
         ]. There may be soft tissue or perineural invasion and sheets of plasma cells. Monoclonal B-cell populations can be found in both benign and malignant lymphoid proliferation. Aberrant expression of CD5 and CD43 by the infiltrating B-cell population is a manifestation of lymphoma.
        </p>
        <p class="headingAnchor" id="H52196786">
         <span class="h4">
          Lymphoma type and features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Marginal zone lymphomas are generally viewed as the most common histologic type in SjD. They are most often extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (also called MALT lymphoma), particularly involving the parotid gland [
         <a href="#rid179">
          179
         </a>
         ]. SjD patients have a 1000-fold increased risk of MALT lymphoma of the parotid gland [
         <a href="#rid6">
          6
         </a>
         ], and most patients with this lymphoma have either underlying SjD or hepatitis C infection [
         <a href="#rid180">
          180
         </a>
         ]. Other sites of MALT lymphoma involvement in SjD include the orbital adnexa, nasopharynx, thyroid, stomach, and lung. (See
         <a class="medical medical_review" href="/z/d/html/4733.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT)"
         </a>
         .)
        </p>
        <p>
         Diffuse large B-cell lymphoma is also associated with SjD; in some cohorts it is more prevalent than MALT lymphomas [
         <a href="#rid29">
          29
         </a>
         ], likely reflecting that they are the most common form of lymphoma in the general population. Among 77 patients with SjD and lymphoma (from a Greek cohort of 712 followed for up to 20 years), MALT lymphoma was the most common non-Hodgkin lymphoma subtype (66 percent), followed by diffuse large B-cell lymphoma (16 percent), and nodal marginal zone lymphoma (10 percent) [
         <a href="#rid161">
          161
         </a>
         ]. In several case studies, transformation of a MALT lymphoma to diffuse large B-cell lymphoma has been documented by molecular analyses. This is estimated to occur in 10 percent of MALT lymphomas. (See
         <a class="medical medical_review" href="/z/d/html/4703.html" rel="external">
          "Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma"
         </a>
         .)
        </p>
        <p>
         MALT lymphomas in SjD usually involve the parotid gland and typically present as a unilateral, firm to hard mass [
         <a href="#rid181">
          181
         </a>
         ]. Regional lymph node involvement is uncommon at presentation. The parotid MALT lymphomas are low-grade indolent neoplasms with 15-year relative survival of close to 80 percent [
         <a href="#rid181">
          181
         </a>
         ]. SjD patients with persistent salivary gland enlargement, particularly when unilateral or asymmetric, should be investigated for lymphoma. This requires either an excisional or a core needle biopsy [
         <a href="#rid182">
          182
         </a>
         ]; fine needle aspiration of lymphoma is subject to a high error rate in the head and neck [
         <a href="#rid183">
          183
         </a>
         ], particularly since monoclonal B-cell populations can be seen in benign lymphoproliferation.
        </p>
        <p class="headingAnchor" id="H32">
         <span class="h2">
          Pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pregnancy outcomes among patients with SjD are generally similar to those of healthy women. However, women with SjD who have anti-Ro/SSA antibodies are at risk for giving birth to babies with neonatal lupus [
         <a href="#rid184">
          184,185
         </a>
         ]. Among the manifestations of neonatal lupus, the greatest concern is congenital heart block [
         <a href="#rid184">
          184,185
         </a>
         ]. The risk of congenital heart block among the offspring of pregnant SjD women who are anti-Ro/SSA antibody positive has been estimated at approximately 2 to 4 percent. Other features of neonatal lupus include cutaneous manifestations, transient hepatitis, thrombocytopenia, and anemia. The clinical manifestations, prevention, and management of neonatal lupus are described in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6402.html" rel="external">
          "Neonatal lupus: Epidemiology, pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H52197319">
         <span class="h1">
          LABORATORY FINDINGS
         </span>
        </p>
        <p class="headingAnchor" id="H52197409">
         <span class="h2">
          General laboratory testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The laboratory findings in patients with extraglandular manifestations of Sjögren’s disease (SjD) depend in large part on the degree of systemic inflammation and specific organ involvement. Findings may include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute phase reactants – Erythrocyte sedimentation rates (ESR) over 50 mm/hour were observed in 30 percent of 286 primary SjD patients defined by the 2002 American-European Consensus Group (AECG) criteria [
         <a href="#rid30">
          30
         </a>
         ]. These elevated rates were closely correlated with higher levels of serum gammaglobulins [
         <a href="#rid39">
          39
         </a>
         ]. C-reactive protein (CRP) levels may be normal or mildly elevated [
         <a href="#rid186">
          186
         </a>
         ]; higher mean levels are seen in those patients with more cardiovascular risk factors [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hematologic findings – Mild anemia, cytopenias, hypergammaglobulinemia, and other abnormalities may occur. (See
         <a class="local">
          'Hematologic manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blood chemistries – Persistent liver function test abnormalities may be observed in up to 26 percent of patients (see
         <a class="local">
          'Gastrointestinal tract'
         </a>
         above). A low serum bicarbonate and elevated serum creatinine may reflect renal disease.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H53038499">
         <span class="h2">
          Autoantibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serum autoantibodies are present in the majority of patients with SjD, and certain autoantibodies are strongly associated with specific clinical features, possibly contributing directly in some cases to the phenotype of individual patients. Antibodies present in patients with SjD and their clinical associations include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antinuclear antibodies
         </strong>
         – An antinuclear antibody (ANA) titer of ≥1:320 was present in 64 percent of primary SjD patients in the International Sjögren's Syndrome Registry; the most common patterns of immunofluorescent staining were speckled (59 percent), SSA (21 percent), and centromere (10 percent) [
         <a href="#rid8">
          8
         </a>
         ]. A negative ANA test is found in approximately 15 to 40 percent of primary SjD patients; these patients are typically older, with less severe glandular and extraglandular disease [
         <a href="#rid116">
          116,187-191
         </a>
         ]. Patients with a negative fluorescent ANA test may have positive testing for anti-Ro/SSA and anti-La/SSB antibodies on solid phase immunoassays.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anti-Ro/SSA and anti-La/SSB antibodies
         </strong>
         – These antibodies are found in the majority of SjD patients and generally identify patients who are younger and have more severe glandular inflammation and extraglandular disease [
         <a href="#rid187">
          187-189
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/1818.html" rel="external">
          "The anti-Ro/SSA and anti-La/SSB antigen-antibody systems", section on 'Sjögren's disease'
         </a>
         ). Of interest, patients lacking these antibodies reported more severe chronic pain and reduced physical function in one study [
         <a href="#rid192">
          192
         </a>
         ]. In addition, patients with pure sensory neuropathy tend to have a lower frequency of these antibodies (and other markers of B-activation) than patients without this form of neuropathy [
         <a href="#rid193">
          193,194
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The anti-Ro/SSA reactivity is comprised of antibodies to two distinct non-homologous proteins, Ro52 and Ro60. Antibodies to both Ro52 and Ro60 coexist in the majority of SSA-positive SjD patients, often in association with anti-La/SSB antibodies [
         <a href="#rid195">
          195,196
         </a>
         ] and define a subgroup with more robust disease [
         <a href="#rid197">
          197
         </a>
         ]. Anti-Ro/SSA and/or anti-La/SSB antibodies may be found in healthy individuals. The prevalence of anti-SSA antibodies was 0.54 percent in the National Health and Nutrition Examination Survey of the United States population [
         <a href="#rid198">
          198
         </a>
         ]. However, it is rare for the reactivity to be directed against more than one of the three SSA/SSB specificities in healthy individuals [
         <a href="#rid195">
          195
         </a>
         ]. Transplacental passage of these antibodies, particularly anti-Ro52, from mother to fetus may result in congenital heart block. (See
         <a class="local">
          'Pregnancy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6402.html" rel="external">
          "Neonatal lupus: Epidemiology, pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rheumatoid factor
         </strong>
         – Approximately 40 to 70 percent of SjD patients have rheumatoid factor (RF) [
         <a href="#rid199">
          199
         </a>
         ], usually of the IgM or IgA isotype (see
         <a class="medical medical_review" href="/z/d/html/1824.html" rel="external">
          "Rheumatoid factor: Biology and utility of measurement"
         </a>
         ). In SjD, RF is associated with younger age, other serologic abnormalities (such as hypergammaglobulinemia, cryoglobulinemia, hypocomplementemia, and anti-SSA/SSB antibodies), and more frequent occurrence of extraglandular manifestations. The presence of RF is not a marker of concomitant rheumatoid arthritis (RA) in SjD; the vast majority of primary SjD patients with RF lack anti-cyclic citrullinated peptide antibodies (ACPA), a more specific marker of RA. (See
         <a class="medical medical_review" href="/z/d/html/7503.html" rel="external">
          "Biologic markers in the assessment of rheumatoid arthritis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Centromere antibodies
         </strong>
         – Antibodies to centromere proteins (usually centromere protein B) are found in approximately 5 to 10 percent of SjD patients and are identified by a centromere staining pattern on the immunofluorescence assay for ANA or by a specific solid-phase assay. They define a subset of patients who are often older and have more frequent Raynaud phenomenon, and less frequent anti-Ro/SSA and anti-La/SSB antibodies, RF, and hyperglobulinemia [
         <a href="#rid27">
          27
         </a>
         ]. The sicca manifestations of these patients may be profound. Some may have features of limited scleroderma and may meet the 2013 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) criteria for systemic sclerosis [
         <a href="#rid200">
          200
         </a>
         ]. In addition to Raynaud phenomenon, these include macular telangiectasia of the palms and face, nailfold capillary telangiectasia, and sclerodactyly.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anti-citrullinated peptide antibodies
         </strong>
         – ACPA, detected by assays for anti-cyclic citrullinated peptide (CCP) antibodies, are present in approximately 5 to 22 percent of SjD patients and correlate with more severe articular manifestations and a higher risk of progression to RA [
         <a href="#rid51">
          51,52,201-203
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antimitochondrial antibodies
         </strong>
         – Antimitochondrial antibodies are sometimes detected in patients with SjD. They are highly specific markers of primary biliary cholangitis (PBC; previously referred to as primary biliary cirrhosis). In a meta-analysis of 24 studies, these antibodies had a pooled sensitivity of 85 percent and specificity of 98 percent for PBC [
         <a href="#rid204">
          204
         </a>
         ]. Antimitochondrial antibodies are present in 1.7 to 13 percent of SjD patients, depending upon the cohort and assay method [
         <a href="#rid205">
          205
         </a>
         ], and are associated with the presence of liver disease. However, not all SjD patients with antimitochondrial antibodies have clinical evidence of liver disease. In a Spanish cohort of 335 patients, 28 (8 percent) had antimitochondrial antibodies, of whom 14 had clinical or laboratory evidence of liver disease [
         <a href="#rid116">
          116
         </a>
         ]. Liver biopsies in four of the patients with liver abnormalities showed PBC in only two. Antimitochondrial antibodies are also associated with Raynaud phenomenon, hypergammaglobulinemia, and peripheral neuropathy in SjD [
         <a href="#rid116">
          116
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H35">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/85725.html" rel="external">
          "Patient education: Sjögren's disease (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/580.html" rel="external">
          "Patient education: Sjögren's disease (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H36">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with Sjögren’s disease (SjD) may have involvement of many types of organs beyond the exocrine glands. Some extraglandular manifestations result from SjD itself, while others result from comorbid rheumatic or other autoimmune disease. (See
         <a class="local">
          'Extraglandular organ involvement'
         </a>
         above and
         <a class="local">
          'Disease spectrum'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The major skin findings in SjD include xerosis (ie, abnormal dryness); purpura, associated with vascular or hematologic abnormalities; Raynaud phenomenon; cutaneous vasculitis; annular erythema; and other manifestations, including eyelid dermatitis and angular cheilitis. Although cutaneous vasculitis occurs in a significant minority of patients, systemic necrotizing vasculitis is rare. (See
         <a class="local">
          'Skin'
         </a>
         above and
         <a class="local">
          'Xerosis'
         </a>
         above and
         <a class="local">
          'Raynaud phenomenon'
         </a>
         above and
         <a class="local">
          'Cutaneous vasculitis'
         </a>
         above and
         <a class="local">
          'Annular erythema'
         </a>
         above and
         <a class="local">
          'Other skin lesions'
         </a>
         above and
         <a class="local">
          'Vasculitis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         SjD may be associated with both joint and muscle manifestations, including arthralgia and (less often) arthritis, as well as myopathy, which is often asymptomatic. Fatigue is one of the most common complaints in SjD, but its pathogenesis is incompletely understood. Patients with SjD suffer from sleep disorders, usually due to disruption of sleep patterns by a cycle of xerostomia-stimulating polydipsia with resultant polyuria. Fibromyalgia, usually accompanied by fatigue, is also very common in SjD. (See
         <a class="local">
          'Musculoskeletal'
         </a>
         above and
         <a class="local">
          'Joints'
         </a>
         above and
         <a class="local">
          'Muscles'
         </a>
         above and
         <a class="local">
          'Fatigue and fibromyalgia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evidence of thyroid disease, including some form of structural, hormonal, or thyroid autoantibody abnormalities, has been found in 10 to 70 percent of patients with primary SjD in geographically diverse studies, with autoimmune thyroiditis being most common. However, whether thyroid disease has a direct relationship to SjD remains uncertain. (See
         <a class="local">
          'Thyroid disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The upper respiratory tract, large and small airways, and interstitium are the primary targets of lung disease in SjD. About 10 to 20 percent of SjD patients have clinically significant lung disease defined by symptoms, typically cough and dyspnea, and an abnormal pulmonary function test or chest radiograph; a greater number of patients have lung abnormalities detectable with additional techniques. Thin-walled lung cysts are detected with CT imaging in 12 to 46 percent of SjD patients, often in association with other radiographic abnormalities. Most SjD patients with cystic lung disease are asymptomatic. Interstitial lung disease can occur in SjD in several forms, including non-specific interstitial pneumonitis (NSIP), usual interstitial pneumonitis (UIP), lymphocytic interstitial pneumonitis (LIP), and cryptogenic organizing pneumonia (COP). (See
         <a class="local">
          'Lungs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         SjD can cause a complex array of peripheral nervous system (PNS) and brain abnormalities. Peripheral neuropathy affects about 10 percent of patients. Estimates of central nervous system (CNS) involvement vary quite widely, and the nature and frequency of CNS manifestations remain controversial. Neuropathic symptoms frequently precede the diagnosis of SjD. (See
         <a class="local">
          'Neurologic disease'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/120953.html" rel="external">
          "Neurologic manifestations of Sjögren's disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Affective disorders, including depression, are the most common psychiatric disturbance in SjD patients. The pathophysiologic basis of depression in SjD is not known; a response to the stress of chronic illness and an effect of cytokines on neural pathways have each been postulated as having a role. (See
         <a class="local">
          'Psychiatric disorders'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The hematologic manifestations of SjD include cytopenias, especially mild anemia and leukopenia; hypergammaglobulinemia; monoclonal gammopathies, cryoglobulinemia, and lymphoma, and are primarily seen in patients with autoantibodies (particularly anti-SSA/Ro or anti-SSB/La antibodies). The lifetime risk of non-Hodgkin lymphoma in SjD is approximately 5 to 10 percent. Non-Hodgkin lymphoma occurs at a mean of approximately seven years after the diagnosis of SjD. (See
         <a class="local">
          'Hematologic manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other areas may also be involved. The heart and cardiovascular system can be affected, with increased risk of cardiovascular disease. Manifestations related to the entire gastrointestinal tract, as well as the liver and pancreas, have been described, including dysphagia, nausea, dyspepsia and gastritis, celiac disease, hepatic abnormalities, and (usually subclinical) pancreatic disease, in addition to oral involvement. Immune-mediated renal disease, including interstitial nephritis, can occur in patients with SjD; as may bladder dysfunction, with symptoms of interstitial nephritis and gynecologic symptoms, including vulvovaginal dryness, pruritus, and dyspareunia. (See
         <a class="local">
          'Heart and cardiovascular system'
         </a>
         above and
         <a class="local">
          'Gastrointestinal tract'
         </a>
         above and
         <a class="local">
          'Urogenital disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Certain serologic findings correlate highly with specific clinical features in SjD. Common serologic findings include antinuclear antibodies (ANA), anti-Ro/SSA and anti-La/SSB antibodies, rheumatoid factor (RF), cryoglobulinemia, and hypocomplementemia. The risk of congenital heart block among the offspring of pregnant SjD women who are anti-Ro/SSA antibody-positive is approximately 3 to 4 percent. Other laboratory findings in patients with extraglandular manifestations of SjD depend largely upon the degree of systemic inflammation and specific organ involvement. (See
         <a class="local">
          'Autoantibodies'
         </a>
         above and
         <a class="local">
          'Pregnancy'
         </a>
         above and
         <a class="local">
          'Laboratory findings'
         </a>
         above and
         <a class="local">
          'General laboratory testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1651249265">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Paul Creamer, MD, and Samuel Moschella, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Asmussen K, Andersen V, Bendixen G, et al. A new model for classification of disease manifestations in primary Sjögren's syndrome: evaluation in a retrospective long-term study. J Intern Med 1996; 239:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos-Casals M, Tzioufas AG, Font J. Primary Sjögren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis 2005; 64:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pertovaara M, Korpela M, Uusitalo H, et al. Clinical follow up study of 87 patients with sicca symptoms (dryness of eyes or mouth, or both). Ann Rheum Dis 1999; 58:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oxholm P, Asmussen K. Primary Sjögren's syndrome: the challenge for classification of disease manifestations. J Intern Med 1996; 239:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lockshin MD, Levine AB, Erkan D. Patients with overlap autoimmune disease differ from those with 'pure' disease. Lupus Sci Med 2015; 2:e000084.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ekström Smedby K, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008; 111:4029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012; 64:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malladi AS, Sack KE, Shiboski SC, et al. Primary Sjögren's syndrome as a systemic disease: a study of participants enrolled in an international Sjögren's syndrome registry. Arthritis Care Res (Hoboken) 2012; 64:911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61:554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vitali C. Classification criteria for Sjögren's syndrome. Ann Rheum Dis 2003; 62:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: A consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 2017; 76:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis Rheumatol 2017; 69:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kittridge A, Routhouska SB, Korman NJ. Dermatologic manifestations of Sjögren syndrome. J Cutan Med Surg 2011; 15:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roguedas AM, Misery L, Sassolas B, et al. Cutaneous manifestations of primary Sjögren's syndrome are underestimated. Clin Exp Rheumatol 2004; 22:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Provost TT, Watson R. Cutaneous manifestations of Sjögren's syndrome. Rheum Dis Clin North Am 1992; 18:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernacchi E, Amato L, Parodi A, et al. Sjögren's syndrome: a retrospective review of the cutaneous features of 93 patients by the Italian Group of Immunodermatology. Clin Exp Rheumatol 2004; 22:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernacchi E, Bianchi B, Amato L, et al. Xerosis in primary Sjögren syndrome: immunohistochemical and functional investigations. J Dermatol Sci 2005; 39:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ELLMAN P, WEBER FP, GOODIER TE. A contribution to the pathology of Sjögren's disease. Q J Med 1951; 20:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orgeolet L, Foulquier N, Misery L, et al. Can artificial intelligence replace manual search for systematic literature? Review on cutaneous manifestations in primary Sjögren's syndrome. Rheumatology (Oxford) 2020; 59:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Villon C, Orgeolet L, Roguedas AM, et al. Epidemiology of cutaneous involvement in Sjögren syndrome: Data from three French pSS populations (TEARS, ASSESS, diapSS). Joint Bone Spine 2021; 88:105162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katayama I, Yokozeki H, Nishioka K. Impaired sweating as an exocrine manifestation in Sjögren's syndrome. Br J Dermatol 1995; 133:716.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rees JL. Sweating in Sjögrens syndrome. Br J Dermatol 1996; 135:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olewicz-Gawlik A, Polańska A, Trzybulska D, et al. Skin Barrier Function in Patients with Primary and Secondary Sjögren's Syndrome. Acta Dermatovenerol Croat 2018; 26:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell J, Greenspan J, Daniels T, et al. Anhidrosis (hypohidrosis) in Sjögren's syndrome. J Am Acad Dermatol 1987; 16:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kraus A, Caballero-Uribe C, Jakez J, et al. Raynaud's phenomenon in primary Sjögren's syndrome. Association with other extraglandular manifestations. J Rheumatol 1992; 19:1572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           García-Carrasco M, Sisó A, Ramos-Casals M, et al. Raynaud's phenomenon in primary Sjögren's syndrome. Prevalence and clinical characteristics in a series of 320 patients. J Rheumatol 2002; 29:726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baer AN, Medrano L, McAdams-DeMarco M, Gniadek TJ. Association of Anticentromere Antibodies With More Severe Exocrine Glandular Dysfunction in Sjögren's Syndrome: Analysis of the Sjögren's International Collaborative Clinical Alliance Cohort. Arthritis Care Res (Hoboken) 2016; 68:1554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM. Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 2009; 88:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Theander E, Henriksson G, Ljungberg O, et al. Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006; 65:796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos-Casals M, Brito-Zerón P, Perez-De-Lis M, et al. Sjögren syndrome or sjögren disease? The histological and immunological bias caused by the 2002 criteria. Clin Rev Allergy Immunol 2010; 38:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox RI, Liu AY. Sjögren's syndrome in dermatology. Clin Dermatol 2006; 24:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos-Casals M, Anaya JM, García-Carrasco M, et al. Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore) 2004; 83:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molina R, Provost TT, Alexander EL. Two types of inflammatory vascular disease in Sjögren's syndrome. Differential association with seroreactivity to rheumatoid factor and antibodies to Ro (SS-A) and with hypocomplementemia. Arthritis Rheum 1985; 28:1251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapnick SL, Merkel PA. Skin ulcers in a patient with Sjögren's syndrome. Arthritis Care Res (Hoboken) 2010; 62:1040.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           García-Carrasco M, Ramos-Casals M, Rosas J, et al. Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore) 2002; 81:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferreiro JE, Pasarin G, Quesada R, Gould E. Benign hypergammaglobulinemic purpura of Waldenström associated with Sjögren's syndrome. Case report and review of immunologic aspects. Am J Med 1986; 81:734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malaviya AN, Kaushik P, Budhiraja S, et al. Hypergammaglobulinemic purpura of Waldenström: report of 3 cases with a short review. Clin Exp Rheumatol 2000; 18:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quartuccio L, Isola M, Baldini C, et al. Clinical and biological differences between cryoglobulinaemic and hypergammaglobulinaemic purpura in primary Sjögren's syndrome: results of a large multicentre study. Scand J Rheumatol 2015; 44:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos-Casals M, Font J, Garcia-Carrasco M, et al. Primary Sjögren syndrome: hematologic patterns of disease expression. Medicine (Baltimore) 2002; 81:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis Rheum 1999; 42:1765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brito-Zerón P, Retamozo S, Akasbi M, et al. Annular erythema in primary Sjogren's syndrome: description of 43 non-Asian cases. Lupus 2014; 23:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katayama I, Kotobuki Y, Kiyohara E, Murota H. Annular erythema associated with Sjögren's syndrome: review of the literature on the management and clinical analysis of skin lesions. Mod Rheumatol 2010; 20:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aydogan K, Karadogan S, Balaban Adim S, Tunali S. Lupus erythematosus associated with erythema multiforme: report of two cases and review of the literature. J Eur Acad Dermatol Venereol 2005; 19:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sato M, Saga K, Takahashi H. Postmenopausal frontal fibrosing alopecia in a Japanese woman with Sjögren's syndrome. J Dermatol 2008; 35:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoneyama K, Tochigi N, Oikawa A, et al. Primary localized cutaneous nodular amyloidosis in a patient with Sjögren's syndrome: a review of the literature. J Dermatol 2005; 32:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pease CT, Shattles W, Barrett NK, Maini RN. The arthropathy of Sjögren's syndrome. Br J Rheumatol 1993; 32:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amezcua-Guerra LM, Hofmann F, Vargas A, et al. Joint involvement in primary Sjögren's syndrome: an ultrasound "target area approach to arthritis". Biomed Res Int 2013; 2013:640265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iagnocco A, Modesti M, Priori R, et al. Subclinical synovitis in primary Sjögren's syndrome: an ultrasonographic study. Rheumatology (Oxford) 2010; 49:1153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lei L, Morgan S, Ntatsaki E, Ciurtin C. Comparative Assessment of Hand Joint Ultrasound Findings in Symptomatic Patients with Systemic Lupus Erythematosus and Sjögren's Syndrome: A Pilot Study. Ultrasound Med Biol 2019; 45:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Payet J, Belkhir R, Gottenberg JE, et al. ACPA-positive primary Sjögren's syndrome: true primary or rheumatoid arthritis-associated Sjögren's syndrome? RMD Open 2015; 1:e000066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohammed K, Pope J, Le Riche N, et al. Association of severe inflammatory polyarthritis in primary Sjögren's syndrome: clinical, serologic, and HLA analysis. J Rheumatol 2009; 36:1937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryu YS, Park SH, Lee J, et al. Follow-up of primary Sjogren's syndrome patients presenting positive anti-cyclic citrullinated peptides antibody. Rheumatol Int 2013; 33:1443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamali S, Polat NG, Kasapoglu E, et al. Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sjögren's syndrome, and Wegener's granulomatosis. Clin Rheumatol 2005; 24:673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molano-González N, Olivares-Martínez E, Anaya JM, Hernández-Molina G. Anti-citrullinated protein antibodies and arthritis in Sjögren's syndrome: a systematic review and meta-analysis. Scand J Rheumatol 2019; 48:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Felten R, Giannini M, Nespola B, et al. Refining myositis associated with primary Sjögren's syndrome: data from the prospective cohort ASSESS. Rheumatology (Oxford) 2021; 60:675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanellopoulos P, Baltoyiannis C, Tzioufas AG. Primary Sjögren's syndrome associated with inclusion body myositis. Rheumatology (Oxford) 2002; 41:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dobloug GC, Antal EA, Sveberg L, et al. High prevalence of inclusion body myositis in Norway; a population-based clinical epidemiology study. Eur J Neurol 2015; 22:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rietveld A, van den Hoogen LL, Bizzaro N, et al. Autoantibodies to Cytosolic 5'-Nucleotidase 1A in Primary Sjögren's Syndrome and Systemic Lupus Erythematosus. Front Immunol 2018; 9:1200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barendregt PJ, Visser MR, Smets EM, et al. Fatigue in primary Sjögren's syndrome. Ann Rheum Dis 1998; 57:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howard Tripp N, Tarn J, Natasari A, et al. Fatigue in primary Sjögren's syndrome is associated with lower levels of proinflammatory cytokines. RMD Open 2016; 2:e000282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Posada J, Valadkhan S, Burge D, et al. Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren's Syndrome: A Randomized Clinical Trial. Arthritis Rheumatol 2021; 73:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008; 67:1541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bowman SJ, Everett CC, O'Dwyer JL, et al. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome. Arthritis Rheumatol 2017; 69:1440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gudbjörnsson B, Broman JE, Hetta J, Hällgren R. Sleep disturbances in patients with primary Sjögren's syndrome. Br J Rheumatol 1993; 32:1072.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torrente-Segarra V, Corominas H, Sánchez-Piedra C, et al. Fibromyalgia prevalence and associated factors in primary Sjögren's syndrome patients in a large cohort from the Spanish Society of Rheumatology registry (SJOGRENSER). Clin Exp Rheumatol 2017; 35 Suppl 105:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi BY, Oh HJ, Lee YJ, Song YW. Prevalence and clinical impact of fibromyalgia in patients with primary Sjögren's syndrome. Clin Exp Rheumatol 2016; 34:S9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goebel A, Krock E, Gentry C, et al. Passive transfer of fibromyalgia symptoms from patients to mice. J Clin Invest 2021; 131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bloch KJ, Buchanan WW, Wohl MJ, Bunim JJ. Sjoegren's syndrome. A clinical, pathological, and serological study of sixty-two cases. Medicine (Baltimore) 1965; 44:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foster H, Fay A, Kelly C, et al. Thyroid disease and other autoimmune phenomena in a family study of primary Sjögren's syndrome. Br J Rheumatol 1993; 32:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pérez B, Kraus A, López G, et al. Autoimmune thyroid disease in primary Sjögren's syndrome. Am J Med 1995; 99:480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Arbonneau F, Ansart S, Le Berre R, et al. Thyroid dysfunction in primary Sjögren's syndrome: a long-term followup study. Arthritis Rheum 2003; 49:804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Girón-Pïllado M, Cruz-Bautista I, Saavedra-González V, et al. Autoimmune Thyroid Disease in Primary Sjögren's Syndrome: Real-life Screening Practice and Clinical Outcomes. Curr Rheumatol Rev 2022; 18:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baldini C, Ferro F, Mosca M, et al. The Association of Sjögren Syndrome and Autoimmune Thyroid Disorders. Front Endocrinol (Lausanne) 2018; 9:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rojas-Villarraga A, Amaya-Amaya J, Rodriguez-Rodriguez A, et al. Introducing polyautoimmunity: secondary autoimmune diseases no longer exist. Autoimmune Dis 2012; 2012:254319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lu MC, Yin WY, Tsai TY, et al. Increased risk of primary Sjögren's syndrome in female patients with thyroid disorders: a longitudinal population-based study in Taiwan. PLoS One 2013; 8:e77210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anaya JM, Tobon GJ, Vega P, Castiblanco J. Autoimmune disease aggregation in families with primary Sjögren's syndrome. J Rheumatol 2006; 33:2227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos-Casals M, García-Carrasco M, Cervera R, et al. Thyroid disease in primary Sjögren syndrome. Study in a series of 160 patients. Medicine (Baltimore) 2000; 79:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tunc R, Gonen MS, Acbay O, et al. Autoimmune thyroiditis and anti-thyroid antibodies in primary Sjogren's syndrome: a case-control study. Ann Rheum Dis 2004; 63:575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsuyama N, Ashizawa K, Okimoto T, et al. Pulmonary lesions associated with Sjögren's syndrome: radiographic and CT findings. Br J Radiol 2003; 76:880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moyron-Quiroz JE, Rangel-Moreno J, Kusser K, et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat Med 2004; 10:927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hatron PY, Tillie-Leblond I, Launay D, et al. Pulmonary manifestations of Sjögren's syndrome. Presse Med 2011; 40:e49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kreider M, Highland K. Pulmonary involvement in Sjögren syndrome. Semin Respir Crit Care Med 2014; 35:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee AS, Scofield RH, Hammitt KM, et al. Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's. Chest 2021; 159:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freeman SR, Sheehan PZ, Thorpe MA, Rutka JA. Ear, nose, and throat manifestations of Sjögren's syndrome: retrospective review of a multidisciplinary clinic. J Otolaryngol 2005; 34:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okabayashi H, Baba T, Ootoshi R, et al. Evaluation of lymphocytic infiltration in the bronchial glands of Sjögren's syndrome in transbronchial lung cryobiopsy. BMC Pulm Med 2020; 20:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakanishi M, Fukuoka J, Tanaka T, et al. Small airway disease associated with Sjögren's syndrome: clinico-pathological correlations. Respir Med 2011; 105:1931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shi JH, Liu HR, Xu WB, et al. Pulmonary manifestations of Sjögren's syndrome. Respiration 2009; 78:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yousem SA, Colby TV, Carrington CB. Follicular bronchitis/bronchiolitis. Hum Pathol 1985; 16:700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lechtman S, Debray MP, Crestani B, et al. Cystic lung disease in Sjögren's syndrome: An observational study. Joint Bone Spine 2017; 84:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martínez-Balzano CD, Touray S, Kopec S. Cystic Lung Disease Among Patients With Sjögren Syndrome: Frequency, Natural History, and Associated Risk Factors. Chest 2016; 150:631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta N, Wikenheiser-Brokamp KA, Fischer A, McCormack FX. Diffuse Cystic Lung Disease as the Presenting Manifestation of Sjögren Syndrome. Ann Am Thorac Soc 2016; 13:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ito I, Nagai S, Kitaichi M, et al. Pulmonary manifestations of primary Sjogren's syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med 2005; 171:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parambil JG, Myers JL, Lindell RM, et al. Interstitial lung disease in primary Sjögren syndrome. Chest 2006; 130:1489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161:646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yong WC, Sanguankeo A, Upala S. Association between primary Sjogren's syndrome, arterial stiffness, and subclinical atherosclerosis: a systematic review and meta-analysis. Clin Rheumatol 2019; 38:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Novella-Navarro M, Cabrera-Alarcón JL, Rosales-Alexander JL, et al. Primary Sjögren's syndrome as independent risk factor for subclinical atherosclerosis. Eur J Rheumatol 2022; 9:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartoloni E, Baldini C, Schillaci G, et al. Cardiovascular disease risk burden in primary Sjögren's syndrome: results of a population-based multicentre cohort study. J Intern Med 2015; 278:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mofors J, Holmqvist M, Westermark L, et al. Concomitant Ro/SSA and La/SSB antibodies are biomarkers for the risk of venous thromboembolism and cerebral infarction in primary Sjögren's syndrome. J Intern Med 2019; 286:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yong WC, Sanguankeo A, Upala S. Association between primary Sjögren's syndrome, cardiovascular and cerebrovascular disease: a systematic review and meta-analysis. Clin Exp Rheumatol 2018; 36 Suppl 112:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Juarez M, Toms TE, de Pablo P, et al. Cardiovascular risk factors in women with primary Sjögren's syndrome: United Kingdom primary Sjögren's syndrome registry results. Arthritis Care Res (Hoboken) 2014; 66:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pérez-De-Lis M, Akasbi M, Sisó A, et al. Cardiovascular risk factors in primary Sjögren's syndrome: a case-control study in 624 patients. Lupus 2010; 19:941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luni FK, Malik SA, Khan AR, et al. Risk of Ischemic Heart Disease in Patients With Sjögren's Syndrome. Am J Med Sci 2017; 354:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gyöngyösi M, Pokorny G, Jambrik Z, et al. Cardiac manifestations in primary Sjögren's syndrome. Ann Rheum Dis 1996; 55:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohri H, Kimura M, Ieki R, et al. Cardiac tamponade in Sjögren's syndrome. J Rheumatol 1986; 13:830.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vassiliou VA, Moyssakis I, Boki KA, Moutsopoulos HM. Is the heart affected in primary Sjögren's syndrome? An echocardiographic study. Clin Exp Rheumatol 2008; 26:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sung MJ, Park SH, Kim SK, et al. Complete atrioventricular block in adult Sjögren's syndrome with anti-Ro autoantibody. Korean J Intern Med 2011; 26:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ebert EC. Gastrointestinal and hepatic manifestations of Sjogren syndrome. J Clin Gastroenterol 2012; 46:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramirez-Mata M, Pena Ancira FF, Alarcon-Segovia D. Abnormal esophageal motility in primary Sjögren's syndrome. J Rheumatol 1976; 3:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palma R, Freire A, Freitas J, et al. Esophageal motility disorders in patients with Sjögren's syndrome. Dig Dis Sci 1994; 39:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rhodus NL, Colby S, Moller K, Bereuter J. Quantitative assessment of dysphagia in patients with primary and secondary Sjögren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995; 79:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zanin MC, Garcia DM, Rocha EM, de Felício CM. Orofacial Motor Functions and Temporomandibular Disorders in Patients With Sjögren's Syndrome. Arthritis Care Res (Hoboken) 2020; 72:1057.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imrich R, Alevizos I, Bebris L, et al. Predominant Glandular Cholinergic Dysautonomia in Patients With Primary Sjögren's Syndrome. Arthritis Rheumatol 2015; 67:1345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maury CP, Törnroth T, Teppo AM. Atrophic gastritis in Sjögren's syndrome. Morphologic, biochemical, and immunologic findings. Arthritis Rheum 1985; 28:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melchor S, Sánchez-Piedra C, Fernández Castro M, et al. Digestive involvement in primary Sjögren's syndrome: analysis from the Sjögrenser registry. Clin Exp Rheumatol 2020; 38 Suppl 126:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kilpi A, Bergroth V, Konttinen YT, et al. Lymphocyte infiltrations of the gastric mucosa in Sjögren's syndrome. An immunoperoxidase study using monoclonal antibodies in the avidin-biotin-peroxidase method. Arthritis Rheum 1983; 26:1196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nardi N, Brito-Zerón P, Ramos-Casals M, et al. Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjögren's syndrome: prevalence and clinical significance in 335 patients. Clin Rheumatol 2006; 25:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alkan S, Karcher DS, Newman MA, Cohen P. Regression of salivary gland MALT lymphoma after treatment for Helicobacter pylori. Lancet 1996; 348:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iwai H, Nakamichi N, Nakae K, et al. Parotid mucosa-associated lymphoid tissue lymphoma regression after Helicobacter pylori eradication. Laryngoscope 2009; 119:1491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartoloni E, Bistoni O, Alunno A, et al. Celiac Disease Prevalence is Increased in Primary Sjögren's Syndrome and Diffuse Systemic Sclerosis: Lessons from a Large Multi-Center Study. J Clin Med 2019; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szodoray P, Barta Z, Lakos G, et al. Coeliac disease in Sjögren's syndrome--a study of 111 Hungarian patients. Rheumatol Int 2004; 24:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skopouli FN, Barbatis C, Moutsopoulos HM. Liver involvement in primary Sjögren's syndrome. Br J Rheumatol 1994; 33:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan MJ, Ike RW. The liver is a common non-exocrine target in primary Sjögren's syndrome: a retrospective review. BMC Gastroenterol 2002; 2:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos-Casals M, Sánchez-Tapias JM, Parés A, et al. Characterization and differentiation of autoimmune versus viral liver involvement in patients with Sjögren's syndrome. J Rheumatol 2006; 33:1593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsianos EV, Hoofnagle JH, Fox PC, et al. Sjögren's syndrome in patients with primary biliary cirrhosis. Hepatology 1990; 11:730.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montaño-Loza AJ, Crispín-Acuña JC, Remes-Troche JM, Uribe M. Abnormal hepatic biochemistries and clinical liver disease in patients with primary Sjögren's syndrome. Ann Hepatol 2007; 6:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Afzelius P, Fallentin EM, Larsen S, et al. Pancreatic function and morphology in Sjögren's syndrome. Scand J Gastroenterol 2010; 45:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsuda M, Hamano H, Yoshida T, et al. Seronegative Sjögren syndrome with asymptomatic autoimmune sclerosing pancreatitis. Clin Rheumatol 2007; 26:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akahane C, Takei Y, Horiuchi A, et al. A primary Sjögren's syndrome patient with marked swelling of multiple exocrine glands and sclerosing pancreatitis. Intern Med 2002; 41:749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leppilahti M, Tammela TL, Huhtala H, et al. Interstitial cystitis-like urinary symptoms among patients with Sjögren's syndrome: a population-based study in Finland. Am J Med 2003; 115:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darrieutort-Laffite C, André V, Hayem G, et al. Sjögren's syndrome complicated by interstitial cystitis: A case series and literature review. Joint Bone Spine 2015; 82:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lehrer S, Bogursky E, Yemini M, et al. Gynecologic manifestations of Sjögren's syndrome. Am J Obstet Gynecol 1994; 170:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skopouli FN, Papanikolaou S, Malamou-Mitsi V, et al. Obstetric and gynaecological profile in patients with primary Sjögren's syndrome. Ann Rheum Dis 1994; 53:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Nimwegen JF, van der Tuuk K, Liefers SC, et al. Vaginal dryness in primary Sjögren's syndrome: a histopathological case-control study. Rheumatology (Oxford) 2020; 59:2806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scofield RH. Vasculitis in Sjögren's Syndrome. Curr Rheumatol Rep 2011; 13:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guellec D, Cornec-Le Gall E, Groh M, et al. ANCA-associated vasculitis in patients with primary Sjögren's syndrome: detailed analysis of 7 new cases and systematic literature review. Autoimmun Rev 2015; 14:742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malinow KL, Molina R, Gordon B, et al. Neuropsychiatric dysfunction in primary Sjögren's syndrome. Ann Intern Med 1985; 103:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harboe E, Tjensvoll AB, Maroni S, et al. Neuropsychiatric syndromes in patients with systemic lupus erythematosus and primary Sjögren syndrome: a comparative population-based study. Ann Rheum Dis 2009; 68:1541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Segal BM, Pogatchnik B, Holker E, et al. Primary Sjogren's syndrome: cognitive symptoms, mood, and cognitive performance. Acta Neurol Scand 2012; 125:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westhoff G, Dörner T, Zink A. Fatigue and depression predict physician visits and work disability in women with primary Sjögren's syndrome: results from a cohort study. Rheumatology (Oxford) 2012; 51:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wen W, Liu Y, Zhao C, et al. Clinical and serologic features of primary Sjögren's syndrome concomitant with autoimmune hemolytic anemia: a large-scale cross-sectional study. Clin Rheumatol 2015; 34:1877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum 2000; 29:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brito-Zerón P, Soria N, Muñoz S, et al. Prevalence and clinical relevance of autoimmune neutropenia in patients with primary Sjögren's syndrome. Semin Arthritis Rheum 2009; 38:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez-Lavin M, Vaughan JH, Tan EM. Autoantibodies and the spectrum of Sjögren's syndrome. Ann Intern Med 1979; 91:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanvetyanon T, Leighton JC. Severe anemia and marrow plasmacytosis as presentation of Sjögren's syndrome. Am J Hematol 2002; 69:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander EL, Arnett FC, Provost TT, Stevens MB. Sjögren's syndrome: association of anti-Ro(SS-A) antibodies with vasculitis, hematologic abnormalities, and serologic hyperreactivity. Ann Intern Med 1983; 98:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brennan MT, Sankar V, Leakan RA, et al. Risk factors for positive minor salivary gland biopsy findings in Sjögren's syndrome and dry mouth patients. Arthritis Rheum 2002; 47:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson LG, Talal N. The spectrum of benign to malignant lymphoproliferation in Sjögren's syndrome. Clin Exp Immunol 1972; 10:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brito-Zerón P, Ramos-Casals M, Nardi N, et al. Circulating monoclonal immunoglobulins in Sjögren syndrome: prevalence and clinical significance in 237 patients. Medicine (Baltimore) 2005; 84:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome. Arthritis Rheum 1996; 39:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Risselada AP, Kruize AA, Bijlsma JW. Clinical features distinguishing lymphoma development in primary Sjögren's Syndrome--a retrospective cohort study. Semin Arthritis Rheum 2013; 43:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weng MY, Huang YT, Liu MF, Lu TH. Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjogren's syndrome in Taiwan. Ann Rheum Dis 2012; 71:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mofors J, Björk A, Smedby KE, et al. Increased risk of multiple myeloma in primary Sjögren's syndrome is limited to individuals with Ro/SSA and La/SSB autoantibodies. Ann Rheum Dis 2020; 79:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang W, Feng S, Yan S, et al. Incidence of malignancy in primary Sjogren's syndrome in a Chinese cohort. Rheumatology (Oxford) 2010; 49:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brito-Zerón P, Kostov B, Fraile G, et al. Characterization and risk estimate of cancer in patients with primary Sjögren syndrome. J Hematol Oncol 2017; 10:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kristinsson SY, Koshiol J, Björkholm M, et al. Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. J Natl Cancer Inst 2010; 102:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos-Casals M, Cervera R, Yagüe J, et al. Cryoglobulinemia in primary Sjögren's syndrome: prevalence and clinical characteristics in a series of 115 patients. Semin Arthritis Rheum 1998; 28:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quartuccio L, Baldini C, Priori R, et al. Cryoglobulinemia in Sjögren Syndrome: A Disease Subset that Links Higher Systemic Disease Activity, Autoimmunity, and Local B Cell Proliferation in Mucosa-associated Lymphoid Tissue. J Rheumatol 2017; 44:1179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005; 165:2337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janin A, Morel P, Quiquandon I, et al. Non-Hodgkin's lymphoma and Sjögren's syndrome. An immunopathological study of 113 patients. Clin Exp Rheumatol 1992; 10:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zufferey P, Meyer OC, Grossin M, Kahn MF. Primary Sjögren's syndrome (SS) and malignant lymphoma. A retrospective cohort study of 55 patients with SS. Scand J Rheumatol 1995; 24:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papageorgiou A, Ziogas DC, Mavragani CP, et al. Predicting the outcome of Sjogren's syndrome-associated non-hodgkin's lymphoma patients. PLoS One 2015; 10:e0116189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazarus MN, Robinson D, Mak V, et al. Incidence of cancer in a cohort of patients with primary Sjogren's syndrome. Rheumatology (Oxford) 2006; 45:1012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kassan SS, Thomas TL, Moutsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978; 89:888.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nocturne G, Mariette X. Sjögren Syndrome-associated lymphomas: an update on pathogenesis and management. Br J Haematol 2015; 168:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishishinya MB, Pereda CA, Muñoz-Fernández S, et al. Identification of lymphoma predictors in patients with primary Sjögren's syndrome: a systematic literature review and meta-analysis. Rheumatol Int 2015; 35:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giannouli S, Voulgarelis M. Predicting progression to lymphoma in Sjögren's syndrome patients. Expert Rev Clin Immunol 2014; 10:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Vita S, Isola M, Baldini C, et al. Predicting lymphoma in Sjögren's syndrome and the pathogenetic role of parotid microenvironment through precise parotid swelling recording. Rheumatology (Oxford) 2023; 62:1586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voulgarelis M, Tzioufas AG, Moutsopoulos HM. Mortality in Sjögren's syndrome. Clin Exp Rheumatol 2008; 26:S66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Risselada AP, Kruize AA, Goldschmeding R, et al. The prognostic value of routinely performed minor salivary gland assessments in primary Sjögren's syndrome. Ann Rheum Dis 2014; 73:1537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Theander E, Vasaitis L, Baecklund E, et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome. Ann Rheum Dis 2011; 70:1363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haacke EA, van der Vegt B, Vissink A, et al. Germinal centres in diagnostic labial gland biopsies of patients with primary Sjögren's syndrome are not predictive for parotid MALT lymphoma development. Ann Rheum Dis 2017; 76:1781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox RI. The importance of minor salivary gland biopsy in prediction of lymphoma in Sjögren's syndrome: should we be obtaining more information about prognosis from minor salivary gland samples? Ann Rheum Dis 2011; 70:1351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nocturne G, Virone A, Ng WF, et al. Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren's Syndrome. Arthritis Rheumatol 2016; 68:977.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tapinos NI, Polihronis M, Moutsopoulos HM. Lymphoma development in Sjögren's syndrome: novel p53 mutations. Arthritis Rheum 1999; 42:1466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carbone A, Gloghini A, Ferlito A. Pathological features of lymphoid proliferations of the salivary glands: lymphoepithelial sialadenitis versus low-grade B-cell lymphoma of the malt type. Ann Otol Rhinol Laryngol 2000; 109:1170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Vita S, De Marchi G, Sacco S, et al. Preliminary classification of nonmalignant B cell proliferation in Sjögren's syndrome: perspectives on pathobiology and treatment based on an integrated clinico-pathologic and molecular study approach. Blood Cells Mol Dis 2001; 27:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurtin PJ. How do you distinguish benign from malignant extranodal small B-cell proliferations? Am J Clin Pathol 1999; 111:S119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyjek E, Smith WJ, Isaacson PG. Primary B-cell lymphoma of salivary glands and its relationship to myoepithelial sialadenitis. Hum Pathol 1988; 19:766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hernández-Molina G, Kostov B, Brito-Zerón P, et al. Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. Rheumatology (Oxford) 2022; 62:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ambrosetti A, Zanotti R, Pattaro C, et al. Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection. Br J Haematol 2004; 126:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vazquez A, Khan MN, Sanghvi S, et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands: a population-based study from 1994 to 2009. Head Neck 2015; 37:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feinstein AJ, Ciarleglio MM, Cong X, et al. Parotid gland lymphoma: prognostic analysis of 2140 patients. Laryngoscope 2013; 123:1199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westra WH. Diagnostic difficulties in the classification and grading of salivary gland tumors. Int J Radiat Oncol Biol Phys 2007; 69:S49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haga HJ, Gjesdal CG, Koksvik HS, et al. Pregnancy outcome in patients with primary Sjögren's syndrome. a case-control study. J Rheumatol 2005; 32:1734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steele JC, Dawson LJ, Moots RJ, Field EA. Congenital heart block associated with undiagnosed maternal Primary Sjögren's Syndrome -- a case report and discussion. Oral Dis 2005; 11:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moutsopoulos HM, Elkon KB, Mavridis AK, et al. Serum C-reactive protein in primary Sjögren's syndrome. Clin Exp Rheumatol 1983; 1:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fossaluzza V, De Vita S. Clinical differences between ANA/anti-ENA positive or negative primary Sjögren's syndrome. Clin Rheumatol 1992; 11:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos-Casals M, Solans R, Rosas J, et al. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 2008; 87:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ter Borg EJ, Risselada AP, Kelder JC. Relation of systemic autoantibodies to the number of extraglandular manifestations in primary Sjögren's Syndrome: a retrospective analysis of 65 patients in the Netherlands. Semin Arthritis Rheum 2011; 40:547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martel C, Gondran G, Launay D, et al. Active immunological profile is associated with systemic Sjögren's syndrome. J Clin Immunol 2011; 31:840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Locht H, Pelck R, Manthorpe R. Clinical manifestations correlated to the prevalence of autoantibodies in a large (n=321) cohort of patients with primary Sjögren's syndrome: a comparison of patients initially diagnosed according to the Copenhagen classification criteria with the American-European consensus criteria. Autoimmun Rev 2005; 4:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Segal BM, Pogatchnik B, Henn L, et al. Pain severity and neuropathic pain symptoms in primary Sjögren's syndrome: a comparison study of seropositive and seronegative Sjögren's syndrome patients. Arthritis Care Res (Hoboken) 2013; 65:1291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jamilloux Y, Magy L, Hurtevent JF, et al. Immunological profiles determine neurological involvement in Sjögren's syndrome. Eur J Intern Med 2014; 25:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sène D, Jallouli M, Lefaucheur JP, et al. Peripheral neuropathies associated with primary Sjögren syndrome: immunologic profiles of nonataxic sensory neuropathy and sensorimotor neuropathy. Medicine (Baltimore) 2011; 90:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garberg H, Jonsson R, Brokstad KA. The serological pattern of autoantibodies to the Ro52, Ro60, and La48 autoantigens in primary Sjögren's syndrome patients and healthy controls. Scand J Rheumatol 2005; 34:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menéndez A, Gómez J, Escanlar E, et al. Clinical associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies: Diagnostic utility of their separate detection. Autoimmunity 2013; 46:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Armağan B, Robinson SA, Bazoberry A, et al. Antibodies to Both Ro52 and Ro60 for Identifying Sjögren's Syndrome Patients Best Suited for Clinical Trials of Disease-Modifying Therapies. Arthritis Care Res (Hoboken) 2022; 74:1559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Satoh M, Chan EK, Ho LA, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum 2012; 64:2319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bournia VK, Vlachoyiannopoulos PG. Subgroups of Sjögren syndrome patients according to serological profiles. J Autoimmun 2012; 39:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65:2737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atzeni F, Sarzi-Puttini P, Lama N, et al. Anti-cyclic citrullinated peptide antibodies in primary Sjögren syndrome may be associated with non-erosive synovitis. Arthritis Res Ther 2008; 10:R51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barcelos F, Abreu I, Patto JV, et al. Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in Sjögren's syndrome. Acta Reumatol Port 2009; 34:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim SM, Park E, Lee JH, et al. The clinical significance of anti-cyclic citrullinated peptide antibody in primary Sjögren syndrome. Rheumatol Int 2012; 32:3963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu S, Zhao F, Wang Q, Chen WX. The accuracy of the anti-mitochondrial antibody and the M2 subtype test for diagnosis of primary biliary cirrhosis: a meta-analysis. Clin Chem Lab Med 2014; 52:1533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang W, Tang D, Lin L, et al. Integrative multiplatform-based molecular profiling of human colorectal cancer reveals proteogenomic alterations underlying mitochondrial inactivation. Am J Cancer Res 2021; 11:2893.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5593 Version 33.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8656140" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : A new model for classification of disease manifestations in primary Sjögren's syndrome: evaluation in a retrospective long-term study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15498797" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Primary Sjögren's syndrome: new clinical and therapeutic concepts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10381486" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Clinical follow up study of 87 patients with sicca symptoms (dryness of eyes or mouth, or both).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8656139" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Primary Sjögren's syndrome: the challenge for classification of disease manifestations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25973214" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Patients with overlap autoimmune disease differ from those with 'pure' disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18263783" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22563590" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22238244" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Primary Sjögren's syndrome as a systemic disease: a study of participants enrolled in an international Sjögren's syndrome registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12006334" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12480687" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Classification criteria for Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27789466" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: A consensus and data-driven methodology involving three international patient cohorts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27785888" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21291650" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Dermatologic manifestations of Sjögren syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15485020" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Cutaneous manifestations of primary Sjögren's syndrome are underestimated.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1496164" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Cutaneous manifestations of Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15005005" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Sjögren's syndrome: a retrospective review of the cutaneous features of 93 patients by the Italian Group of Immunodermatology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15894462" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Xerosis in primary Sjögren syndrome: immunohistochemical and functional investigations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24540157" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A contribution to the pathology of Sjögren's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31504928" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Can artificial intelligence replace manual search for systematic literature? Review on cutaneous manifestations in primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33617999" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Epidemiology of cutaneous involvement in Sjögren syndrome: Data from three French pSS populations (TEARS, ASSESS, diapSS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8555022" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Impaired sweating as an exocrine manifestation in Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8949454" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Sweating in Sjögrens syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29989872" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Skin Barrier Function in Patients with Primary and Secondary Sjögren's Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3819059" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Anhidrosis (hypohidrosis) in Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1464870" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Raynaud's phenomenon in primary Sjögren's syndrome. Association with other extraglandular manifestations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11950013" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Raynaud's phenomenon in primary Sjögren's syndrome. Prevalence and clinical characteristics in a series of 320 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26867144" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Association of Anticentromere Antibodies With More Severe Exocrine Glandular Dysfunction in Sjögren's Syndrome: Analysis of the Sjögren's International Collaborative Clinical Alliance Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19745687" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16284097" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19578996" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Sjögren syndrome or sjögren disease? The histological and immunological bias caused by the 2002 criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16966020" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Sjögren's syndrome in dermatology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15028963" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3877510" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Two types of inflammatory vascular disease in Sjögren's syndrome. Differential association with seroreactivity to rheumatoid factor and antibodies to Ro (SS-A) and with hypocomplementemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20235199" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Skin ulcers in a patient with Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12169882" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3766605" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Benign hypergammaglobulinemic purpura of Waldenström associated with Sjögren's syndrome. Case report and review of immunologic aspects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10949733" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Hypergammaglobulinemic purpura of Waldenström: report of 3 cases with a short review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25268749" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Clinical and biological differences between cryoglobulinaemic and hypergammaglobulinaemic purpura in primary Sjögren's syndrome: results of a large multicentre study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12169883" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Primary Sjögren syndrome: hematologic patterns of disease expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10446879" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24326481" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Annular erythema in primary Sjogren's syndrome: description of 43 non-Asian cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20054701" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Annular erythema associated with Sjögren's syndrome: review of the literature on the management and clinical analysis of skin lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16164723" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Lupus erythematosus associated with erythema multiforme: report of two cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19120768" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Postmenopausal frontal fibrosing alopecia in a Japanese woman with Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15906542" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Primary localized cutaneous nodular amyloidosis in a patient with Sjögren's syndrome: a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8339134" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The arthropathy of Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23936829" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Joint involvement in primary Sjögren's syndrome: an ultrasound "target area approach to arthritis".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20236956" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Subclinical synovitis in primary Sjögren's syndrome: an ultrasonographic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30401509" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Comparative Assessment of Hand Joint Ultrasound Findings in Symptomatic Patients with Systemic Lupus Erythematosus and Sjögren's Syndrome: A Pilot Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26509066" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : ACPA-positive primary Sjögren's syndrome: true primary or rheumatoid arthritis-associated Sjögren's syndrome?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19487261" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Association of severe inflammatory polyarthritis in primary Sjögren's syndrome: clinical, serologic, and HLA analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23179261" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Follow-up of primary Sjogren's syndrome patients presenting positive anti-cyclic citrullinated peptides antibody.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15926038" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sjögren's syndrome, and Wegener's granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30270696" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Anti-citrullinated protein antibodies and arthritis in Sjögren's syndrome: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32780813" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Refining myositis associated with primary Sjögren's syndrome: data from the prospective cohort ASSESS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11961175" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Primary Sjögren's syndrome associated with inclusion body myositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25530508" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : High prevalence of inclusion body myositis in Norway; a population-based clinical epidemiology study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29922285" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Autoantibodies to Cytosolic 5'-Nucleotidase 1A in Primary Sjögren's Syndrome and Systemic Lupus Erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9741313" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Fatigue in primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27493792" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Fatigue in primary Sjögren's syndrome is associated with lower levels of proinflammatory cytokines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32798283" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren's Syndrome: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18276741" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28296257" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8252317" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Sleep disturbances in patients with primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28240585" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Fibromyalgia prevalence and associated factors in primary Sjögren's syndrome patients in a large cohort from the Spanish Society of Rheumatology registry (SJOGRENSER).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26315451" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Prevalence and clinical impact of fibromyalgia in patients with primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34196305" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Passive transfer of fibromyalgia symptoms from patients to mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14315274" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Sjoegren's syndrome. A clinical, pathological, and serological study of sixty-two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8422556" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Thyroid disease and other autoimmune phenomena in a family study of primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7485204" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Autoimmune thyroid disease in primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14673967" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Thyroid dysfunction in primary Sjögren's syndrome: a long-term followup study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35086454" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Autoimmune Thyroid Disease in Primary Sjögren's Syndrome: Real-life Screening Practice and Clinical Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29666604" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : The Association of Sjögren Syndrome and Autoimmune Thyroid Disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22454759" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Introducing polyautoimmunity: secondary autoimmune diseases no longer exist.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24204772" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Increased risk of primary Sjögren's syndrome in female patients with thyroid disorders: a longitudinal population-based study in Taiwan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17086607" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Autoimmune disease aggregation in families with primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10771708" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Thyroid disease in primary Sjögren syndrome. Study in a series of 160 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15082490" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Autoimmune thyroiditis and anti-thyroid antibodies in primary Sjogren's syndrome: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14711775" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Pulmonary lesions associated with Sjögren's syndrome: radiographic and CT findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15311275" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21194883" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Pulmonary manifestations of Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24668540" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Pulmonary involvement in Sjögren syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33075377" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15966471" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Ear, nose, and throat manifestations of Sjögren's syndrome: retrospective review of a multidisciplinary clinic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33097019" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Evaluation of lymphocytic infiltration in the bronchial glands of Sjögren's syndrome in transbronchial lung cryobiopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21903371" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Small airway disease associated with Sjögren's syndrome: clinico-pathological correlations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19390161" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Pulmonary manifestations of Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4007845" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Follicular bronchitis/bronchiolitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27659405" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Cystic lung disease in Sjögren's syndrome: An observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27231156" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Cystic Lung Disease Among Patients With Sjögren Syndrome: Frequency, Natural History, and Associated Risk Factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26741500" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Diffuse Cystic Lung Disease as the Presenting Manifestation of Sjögren Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15579729" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Pulmonary manifestations of primary Sjogren's syndrome: a clinical, radiologic, and pathologic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17099028" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Interstitial lung disease in primary Sjögren syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10673212" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30178172" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Association between primary Sjogren's syndrome, arterial stiffness, and subclinical atherosclerosis: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35110133" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Primary Sjögren's syndrome as independent risk factor for subclinical atherosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25582881" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Cardiovascular disease risk burden in primary Sjögren's syndrome: results of a population-based multicentre cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31127862" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Concomitant Ro/SSA and La/SSB antibodies are biomarkers for the risk of venous thromboembolism and cerebral infarction in primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29600936" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Association between primary Sjögren's syndrome, cardiovascular and cerebrovascular disease: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24877201" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Cardiovascular risk factors in women with primary Sjögren's syndrome: United Kingdom primary Sjögren's syndrome registry results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20581017" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Cardiovascular risk factors in primary Sjögren's syndrome: a case-control study in 624 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29078844" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Risk of Ischemic Heart Disease in Patients With Sjögren's Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8774163" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Cardiac manifestations in primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3772936" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Cardiac tamponade in Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18328155" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Is the heart affected in primary Sjögren's syndrome? An echocardiographic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21716914" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Complete atrioventricular block in adult Sjögren's syndrome with anti-Ro autoantibody.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22157220" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Gastrointestinal and hepatic manifestations of Sjogren syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1271390" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Abnormal esophageal motility in primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8149841" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Esophageal motility disorders in patients with Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7621008" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Quantitative assessment of dysphagia in patients with primary and secondary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31207153" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Orofacial Motor Functions and Temporomandibular Disorders in Patients With Sjögren's Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25622919" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Predominant Glandular Cholinergic Dysautonomia in Patients With Primary Sjögren's Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3885959" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Atrophic gastritis in Sjögren's syndrome. Morphologic, biochemical, and immunologic findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33025900" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Digestive involvement in primary Sjögren's syndrome: analysis from the Sjögrenser registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6354194" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Lymphocyte infiltrations of the gastric mucosa in Sjögren's syndrome. An immunoperoxidase study using monoclonal antibodies in the avidin-biotin-peroxidase method.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16249826" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjögren's syndrome: prevalence and clinical significance in 335 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8684218" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Regression of salivary gland MALT lymphoma after treatment for Helicobacter pylori.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19504556" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Parotid mucosa-associated lymphoid tissue lymphoma regression after Helicobacter pylori eradication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31010199" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Celiac Disease Prevalence is Increased in Primary Sjögren's Syndrome and Diffuse Systemic Sclerosis: Lessons from a Large Multi-Center Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13680146" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Coeliac disease in Sjögren's syndrome--a study of 111 Hungarian patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8055202" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Liver involvement in primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12230633" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : The liver is a common non-exocrine target in primary Sjögren's syndrome: a retrospective review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16881116" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Characterization and differentiation of autoimmune versus viral liver involvement in patients with Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2347546" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Sjögren's syndrome in patients with primary biliary cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17786140" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Abnormal hepatic biochemistries and clinical liver disease in patients with primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20334476" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Pancreatic function and morphology in Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16362447" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Seronegative Sjögren syndrome with asymptomatic autoimmune sclerosing pancreatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12322807" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : A primary Sjögren's syndrome patient with marked swelling of multiple exocrine glands and sclerosing pancreatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12867237" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Interstitial cystitis-like urinary symptoms among patients with Sjögren's syndrome: a population-based study in Finland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25680227" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Sjögren's syndrome complicated by interstitial cystitis: A case series and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8141212" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Gynecologic manifestations of Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7979594" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Obstetric and gynaecological profile in patients with primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32044981" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Vaginal dryness in primary Sjögren's syndrome: a histopathological case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21870104" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Vasculitis in Sjögren's Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25916811" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : ANCA-associated vasculitis in patients with primary Sjögren's syndrome: detailed analysis of 7 new cases and systematic literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2992332" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Neuropsychiatric dysfunction in primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18930990" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Neuropsychiatric syndromes in patients with systemic lupus erythematosus and primary Sjögren syndrome: a comparative population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21651503" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Primary Sjogren's syndrome: cognitive symptoms, mood, and cognitive performance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21705778" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Fatigue and depression predict physician visits and work disability in women with primary Sjögren's syndrome: results from a cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26423426" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Clinical and serologic features of primary Sjögren's syndrome concomitant with autoimmune hemolytic anemia: a large-scale cross-sectional study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10805354" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18378278" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Prevalence and clinical relevance of autoimmune neutropenia in patients with primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/157095" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Autoantibodies and the spectrum of Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11891816" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Severe anemia and marrow plasmacytosis as presentation of Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6600593" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Sjögren's syndrome: association of anti-Ro(SS-A) antibodies with vasculitis, hematologic abnormalities, and serologic hyperreactivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11954013" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Risk factors for positive minor salivary gland biopsy findings in Sjögren's syndrome and dry mouth patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4625796" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : The spectrum of benign to malignant lymphoproliferation in Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15758838" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Circulating monoclonal immunoglobulins in Sjögren syndrome: prevalence and clinical significance in 237 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8639173" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23664530" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Clinical features distinguishing lymphoma development in primary Sjögren's Syndrome--a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22072014" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjogren's syndrome in Taiwan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31694814" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Increased risk of multiple myeloma in primary Sjögren's syndrome is limited to individuals with Ro/SSA and La/SSB autoantibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20040528" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Incidence of malignancy in primary Sjogren's syndrome in a Chinese cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28416003" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Characterization and risk estimate of cancer in patients with primary Sjögren syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20181958" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9872481" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Cryoglobulinemia in primary Sjögren's syndrome: prevalence and clinical characteristics in a series of 115 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28507188" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Cryoglobulinemia in Sjögren Syndrome: A Disease Subset that Links Higher Systemic Disease Activity, Autoimmunity, and Local B Cell Proliferation in Mucosa-associated Lymphoid Tissue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16287762" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : The risk of lymphoma development in autoimmune diseases: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1483307" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Non-Hodgkin's lymphoma and Sjögren's syndrome. An immunopathological study of 113 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8610217" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Primary Sjögren's syndrome (SS) and malignant lymphoma. A retrospective cohort study of 55 patients with SS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25723713" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Predicting the outcome of Sjogren's syndrome-associated non-hodgkin's lymphoma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16490754" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Incidence of cancer in a cohort of patients with primary Sjogren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/102228" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Increased risk of lymphoma in sicca syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25316606" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : Sjögren Syndrome-associated lymphomas: an update on pathogenesis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24899571" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Identification of lymphoma predictors in patients with primary Sjögren's syndrome: a systematic literature review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24451006" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Predicting progression to lymphoma in Sjögren's syndrome patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36063040" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Predicting lymphoma in Sjögren's syndrome and the pathogenetic role of parotid microenvironment through precise parotid swelling recording.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19026146" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : Mortality in Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24525912" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : The prognostic value of routinely performed minor salivary gland assessments in primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21715359" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28710097" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Germinal centres in diagnostic labial gland biopsies of patients with primary Sjögren's syndrome are not predictive for parotid MALT lymphoma development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21715358" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : The importance of minor salivary gland biopsy in prediction of lymphoma in Sjögren's syndrome: should we be obtaining more information about prognosis from minor salivary gland samples?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26606524" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren's Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10403275" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : Lymphoma development in Sjögren's syndrome: novel p53 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11130833" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : Pathological features of lymphoid proliferations of the salivary glands: lymphoepithelial sialadenitis versus low-grade B-cell lymphoma of the malt type.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11778660" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : Preliminary classification of nonmalignant B cell proliferation in Sjögren's syndrome: perspectives on pathobiology and treatment based on an integrated clinico-pathologic and molecular study approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9894476" id="rid176" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          177 : How do you distinguish benign from malignant extranodal small B-cell proliferations?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3136072" id="rid177" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          178 : Primary B-cell lymphoma of salivary glands and its relationship to myoepithelial sialadenitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35385104" id="rid178" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          179 : Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15198730" id="rid179" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          180 : Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24733777" id="rid180" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          181 : Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands: a population-based study from 1994 to 2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23576299" id="rid181" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          182 : Parotid gland lymphoma: prognostic analysis of 2140 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17848294" id="rid182" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          183 : Diagnostic difficulties in the classification and grading of salivary gland tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16142869" id="rid183" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          184 : Pregnancy outcome in patients with primary Sjögren's syndrome. a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15888112" id="rid184" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          185 : Congenital heart block associated with undiagnosed maternal Primary Sjögren's Syndrome -- a case report and discussion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6681127" id="rid185" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          186 : Serum C-reactive protein in primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1458787" id="rid186" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          187 : Clinical differences between ANA/anti-ENA positive or negative primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18626304" id="rid187" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          188 : Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20864144" id="rid188" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          189 : Relation of systemic autoantibodies to the number of extraglandular manifestations in primary Sjögren's Syndrome: a retrospective analysis of 65 patients in the Netherlands.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21744183" id="rid189" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          190 : Active immunological profile is associated with systemic Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15990074" id="rid190" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          191 : Clinical manifestations correlated to the prevalence of autoantibodies in a large (n=321) cohort of patients with primary Sjögren's syndrome: a comparison of patients initially diagnosed according to the Copenhagen classification criteria with the American-European consensus criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23335582" id="rid191" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          192 : Pain severity and neuropathic pain symptoms in primary Sjögren's syndrome: a comparison study of seropositive and seronegative Sjögren's syndrome patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24176941" id="rid192" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          193 : Immunological profiles determine neurological involvement in Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21358442" id="rid193" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          194 : Peripheral neuropathies associated with primary Sjögren syndrome: immunologic profiles of nonataxic sensory neuropathy and sensorimotor neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15903026" id="rid194" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          195 : The serological pattern of autoantibodies to the Ro52, Ro60, and La48 autoantigens in primary Sjögren's syndrome patients and healthy controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23039326" id="rid195" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          196 : Clinical associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies: Diagnostic utility of their separate detection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33742788" id="rid196" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          197 : Antibodies to Both Ro52 and Ro60 for Identifying Sjögren's Syndrome Patients Best Suited for Clinical Trials of Disease-Modifying Therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22237992" id="rid197" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          198 : Prevalence and sociodemographic correlates of antinuclear antibodies in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22575069" id="rid198" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          199 : Subgroups of Sjögren syndrome patients according to serological profiles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24122180" id="rid199" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          200 : 2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League Against Rheumatism collaborative initiative.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18462485" id="rid200" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          201 : Anti-cyclic citrullinated peptide antibodies in primary Sjögren syndrome may be associated with non-erosive synovitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20087267" id="rid201" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          202 : Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22205381" id="rid202" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          203 : The clinical significance of anti-cyclic citrullinated peptide antibody in primary Sjögren syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24501161" id="rid203" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          204 : The accuracy of the anti-mitochondrial antibody and the M2 subtype test for diagnosis of primary biliary cirrhosis: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34249434" id="rid204" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          205 : Integrative multiplatform-based molecular profiling of human colorectal cancer reveals proteogenomic alterations underlying mitochondrial inactivation.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
